<SEC-DOCUMENT>0001193125-22-256794.txt : 20221003
<SEC-HEADER>0001193125-22-256794.hdr.sgml : 20221003
<ACCEPTANCE-DATETIME>20221003171732
ACCESSION NUMBER:		0001193125-22-256794
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20221003
DATE AS OF CHANGE:		20221003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Calyxt, Inc.
		CENTRAL INDEX KEY:			0001705843
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		IRS NUMBER:				271967997
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267499
		FILM NUMBER:		221288543

	BUSINESS ADDRESS:	
		STREET 1:		2800 MOUNT RIDGE ROAD
		CITY:			ROSEVILLE
		STATE:			MN
		ZIP:			55113
		BUSINESS PHONE:		(651) 683-2807

	MAIL ADDRESS:	
		STREET 1:		2800 MOUNT RIDGE ROAD
		CITY:			ROSEVILLE
		STATE:			MN
		ZIP:			55113
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d385878d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:71%; font-size:10pt; font-family:Times New Roman"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration No. 333-267499 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To Prospectus, dated
September&nbsp;19, 2022 </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g385878g14w41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 15,661,000 Shares of Common Stock </B></P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has entered into an Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> (as amended through the date of
this prospectus supplement, the &#147;Sales Agreement&#148;) with Jefferies LLC (&#147;Jefferies&#148;), relating to the sale of shares of Calyxt&#146;s common stock, par value $0.0001 per share (&#147;common stock&#148;), offered by this prospectus
supplement. In accordance with the terms of the Sales Agreement, Calyxt may, pursuant to this prospectus supplement and the accompanying prospectus, offer and sell up to 15,661,000 shares of its common stock from time to time through Jefferies,
acting as agent. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s common stock is listed on the Nasdaq Global Market under the symbol &#147;CLXT.&#148; On September&nbsp;30,
2022, the last reported sale price of Calyxt&#146;s common stock on the Nasdaq Global Market was $0.17 per share. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of Calyxt&#146;s
common stock, if any, under this prospectus supplement and the accompanying prospectus will be made in sales deemed to be &#147;at the market offerings&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;). Jefferies is not required to sell any specific amount of Calyxt&#146;s common stock, but will act as its sales agent and use commercially reasonable efforts to sell on Calyxt&#146;s behalf all of the shares of common
stock requested to be sold by Calyxt, consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and Calyxt. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jefferies will be entitled to compensation under the terms of the Sales Agreement at a commission rate equal to 3.0% of the gross sales price
per share sold. See &#147;Plan of Distribution&#148; beginning on page <FONT STYLE="white-space:nowrap">S-20</FONT> for additional information regarding Jefferies&#146; compensation. In connection with the sale of shares of common stock on
Calyxt&#146;s behalf, Jefferies will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. Calyxt has also agreed to provide
indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the aggregate market value of Calyxt&#146;s outstanding common equity held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> was approximately $3.8&nbsp;million, based on 22,590,500&nbsp;shares of Calyxt&#146;s common stock, par value $0.0001 per share, held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
and a per share price of $0.17, which equaled the closing price of Calyxt&#146;s common stock on such date. Pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in no event will Calyxt sell securities in a
primary offering with a value exceeding more than <FONT STYLE="white-space:nowrap">one-third</FONT> of its public float in any <FONT STYLE="white-space:nowrap">12-month</FONT> period so long as its public float remains below $75,000,000. Calyxt has
sold $388 of securities pursuant to General Instruction 1.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> during the 12 calendar month period that ends on and includes the date of this prospectus supplement (excluding the securities offered
by this prospectus). </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in Calyxt&#146;s common stock involves a high degree of risk. Before making an investment decision, please read the information in
the section titled &#147;<A HREF="#supprom385878_4">Risk Factors</A>&#148; beginning on page S-3 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies
</B></P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is October&nbsp;3, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_10">CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom385878_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_7">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_8">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_10">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_14">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_15">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement that Calyxt filed with the Securities and
Exchange Commission, or the SEC, utilizing a &#147;shelf&#148; registration process. This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates
information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, provides more general information. Generally, when Calyxt refers to this prospectus, it is
referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by
reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document
having a later date&#151;for example, a document incorporated by reference in the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt further notes that the representations, warranties and covenants made by it in any agreement that is filed as an exhibit to any
document that is incorporated by reference herein or in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements,
and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not
be relied on as accurately representing the current state of Calyxt&#146;s affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Calyxt nor Jefferies has authorized anyone to
provide you with information that is different from the information contained or incorporated by reference in this prospectus supplement or the accompanying prospectus and any free writing prospectus prepared by or on behalf of Calyxt or to which
you have been referred by Calyxt. Neither Calyxt nor Jefferies takes any responsibility for or provides any assurance as to the reliability of any other information that others may give you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein or therein, or in
any free writing prospectus that Calyxt has authorized for use in connection with this offering, is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or
of any sale of Calyxt&#146;s securities. Calyxt&#146;s business, financial condition, results of operations and prospects may have changed since those dates. It is important for you to read and consider all information contained in this prospectus
supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which Calyxt has referred you
in the sections entitled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and in the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is offering to sell, and seeking offers to buy, shares of common stock offered by this prospectus supplement only in jurisdictions
where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the shares of common stock offered by this prospectus supplement in certain jurisdictions may be restricted by
law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the
distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a
solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the documents incorporated by reference in this prospectus
supplement contain market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although Calyxt believes that these sources are reliable, it does not guarantee the
accuracy or completeness of this information and Calyxt has not independently verified this information. Although the Company is not aware of any misstatements regarding the market and industry data presented or incorporated by reference in this
prospectus supplement, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &#147;Risk Factors&#148; in this prospectus supplement and any related free
writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout this prospectus, unless the context otherwise requires, the terms &#147;Calyxt,&#148; the &#147;Company&#148; and &#147;it&#148;
refer to Calyxt, Inc. The term &#147;Cellectis&#148; refers to Cellectis S.A., Calyxt&#146;s majority stockholder as of the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt owns the names PlantSpring and BioFactory. Calyxt also owns the trademarks
Calyxt<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Calyno<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and owns or licenses other trademarks, trade names, and service marks appearing in this this prospectus supplement
or any free writing prospectus. The names and trademarks Cellectis<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and TALEN<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, along with any other trademarks, trade names, and
service marks of Cellectis appearing in this this prospectus supplement or any free writing prospectus are the property of Cellectis. This prospectus supplement and any free writing prospectus may also contain additional trade names, trademarks and
service marks belonging to other companies. Calyxt does not intend its use or display of other parties&#146; trademarks, trade names, or service marks to imply, and such use or display should not be construed to imply a relationship with, or
endorsement or sponsorship of these other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus supplement or incorporated by reference in this
prospectus supplement, and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus supplement and accompanying prospectus, and any related free writing
prospectus, including the risks of investing in Calyxt&#146;s securities discussed in the section titled &#147;Risk Factors&#148; contained in this prospectus supplement and any related free writing prospectus, and under similar headings in the
other documents that are incorporated by reference into this prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus supplement, including Calyxt&#146;s financial statements, and the
exhibits to the registration statement of which this prospectus supplement is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is a plant-based synthetic biology company that leverages its proprietary
PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology platform to engineer plant metabolism to produce innovative, high-value plant-based chemistries for use in customers&#146; materials and products. As plant-based
solutions, the Company&#146;s synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. The Company is focused on developing these synthetic biology solutions for customers in large and
differentiated end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries, which are the Company&#146;s initial target markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Cellectis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is
currently a majority-owned subsidiary of Cellectis S.A. As of June&nbsp;30, 2022, Cellectis owned 51.3&nbsp;percent of Calyxt&#146;s 46,715,542 outstanding shares of common stock. Cellectis has certain contractual rights as well as rights pursuant
to Calyxt&#146;s certificate of incorporation and bylaws, in each case, for so long as it maintains threshold beneficial ownership levels in Calyxt&#146;s shares. Several of Cellectis&#146; rights remain in effect for so long as Cellectis
beneficially owns at least 15&nbsp;percent of Calyxt&#146;s outstanding shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt holds an exclusive license from Cellectis that
broadly covers the use of engineered nucleases for plant gene editing. This intellectual property covers methods to edit plant genes using &#147;chimeric restriction endonucleases,&#148; which include TALEN<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, CRISPR/Cas9, zinc finger nucleases, and some types of meganucleases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt was incorporated in the State of Delaware in 2010. The Company&#146;s corporate headquarters is located at 2800 Mount Ridge
Road, Roseville, Minnesota 55113 and Calyxt&#146;s phone number is (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> Calyxt&#146;s filings with the SEC are posted on its corporate website at www.calyxt.com. The information contained in, or
accessible through, Calyxt&#146;s corporate website does not constitute part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s common stock is listed on
the Nasdaq Global Market under the symbol &#147;CLXT.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_3"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Offered by Calyxt </P></TD>
<TD>Up to 15,661,000 shares of Calyxt&#146;s common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Outstanding After this Offering </P></TD>
<TD>Up to 62,376,542 shares, assuming the sale of 15,661,000 shares of Calyxt&#146;s common stock in this offering at a price of $0.17 per share, which was the closing price of Calyxt&#146;s common stock on the Nasdaq Global Market on
September&nbsp;30, 2022. The actual number of shares issued will vary depending on the sales price under this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Plan of Distribution </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through Jefferies LLC, who is acting as sales agent. See &#147;Plan of Distribution&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-20.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>Calyxt currently intends to use the net proceeds from this offering for working capital and general corporate purposes. See the section titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>Investment in Calyxt&#146;s securities involves a high degree of risk. You should read the section titled &#147;Risk Factors&#148; in this prospectus supplement and in the documents incorporated by reference into this prospectus supplement for a
discussion of factors to consider before deciding to purchase shares of Calyxt&#146;s common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market Symbol </P></TD>
<TD>&#147;CLXT&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after this offering is based on 46,715,542
shares outstanding as of June&nbsp;30, 2022, and excludes as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,937,988 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average
exercise price of $7.30 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,406,042 shares of common stock issuable upon the vesting and settlement of restricted stock units outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,130,000 shares of common stock issuable upon the vesting and settlement of performance stock units outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,961,677 shares of common stock reserved for future issuance under Calyxt&#146;s 2017 Omnibus Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,760,000 shares of common stock issuable upon exercise of outstanding warrants to purchase common stock, each
with an exercise price of $1.41 per share (&#147;Common Warrants&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, information in this
prospectus supplement assumes no further exercise of outstanding options or Common Warrants. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the risks described below and under the section titled &#147;Risk Factors&#148; in Calyxt&#146;s Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as may be updated by the Company&#146;s subsequent filings under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;),
that are incorporated by reference in this prospectus supplement in their entirety, together with other information in this prospectus supplement and the information and documents incorporated by reference in this prospectus supplement and any free
writing prospectus that Calyxt may authorize for use in connection with this offering before you make a decision to invest in Calyxt&#146;s&nbsp;securities. If any of these risks actually occur, Calyxt&#146;s business, operating results, prospects
or financial condition could be harmed. This could cause the trading price of Calyxt&#146;s common stock to decline and you may lose all or part of your investment. The risks below and incorporated by reference in this prospectus supplement are not
the only ones Calyxt faces. Additional risks not currently known to Calyxt or that Calyxt currently deems immaterial may also affect Calyxt&#146;s business operations. Please also read carefully the section below titled &#147;Cautionary Note
Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to The Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of Calyxt&#146;s common stock outstanding prior
to this offering. Assuming that an aggregate of 15,661,000 shares of Calyxt&#146;s common stock are sold at a price of $0.17 per share, which was the last reported sale price of Calyxt&#146;s common stock on the Nasdaq Global Market on
September&nbsp;30, 2022, for aggregate gross proceeds of approximately $2.7&nbsp;million, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate accretion of $0.09 per share, representing the
difference between Calyxt&#146;s as adjusted net tangible book value per share as of June&nbsp;30, 2022, after giving effect to this offering, and the assumed public offering price. However, in the future, the price per share of Calyxt&#146;s common
stock being offered may be higher than the net tangible book value per share of Calyxt&#146;s outstanding common stock prior to this offering, in which case new investors would suffer immediate dilution to the extent the public offering price per
share in the offering exceeds the net tangible book value per share of Calyxt&#146;s common stock after this offering. For a further description of the dilution that you will experience immediately after this offering, see the section of this
prospectus supplement titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings or other transactions.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, Calyxt expects in the future to offer additional shares of Calyxt&#146;s common stock or
other securities convertible into or exchangeable for Calyxt&#146;s common stock. For example, Calyxt is evaluating a full range of potential strategic alternatives to maximize shareholder value, certain of which could result in substantial dilution
to existing stockholders and have a material adverse effect on the market price of Calyxt&#146;s common stock. Calyxt cannot assure you that it will be able to sell shares or other securities in any other offering or as part of such strategic
alternatives at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The
price per share at which Calyxt sells additional shares of its common stock or other securities convertible into or exchangeable for its common stock in future transactions may be higher or lower than the price per share in this offering. As of
June&nbsp;30, 2022, approximately 19.7&nbsp;million shares of common stock that are either subject to outstanding options, issuable upon exercise of the outstanding Common Warrants, issuable upon vesting of outstanding restricted stock units, or
reserved for future issuance under Calyxt&#146;s equity incentive plans are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and with respect to the Common Warrants, subject to certain
beneficial ownership limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although the Company is exploring a range of strategic alternatives, there is no certainty that the
Company will be able to execute on any transaction in the near term or at all or that such a transaction will enhance stockholder value, and any such transaction may be highly dilutive to the Company&#146;s stockholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2022 and June&nbsp;30, 2022, the Company had cash, cash equivalents, and restricted cash of $17.9&nbsp;million and
$11.9&nbsp;million, respectively, and current liabilities of $9.5&nbsp;million and $4.5&nbsp;million, respectively. On September&nbsp;22, 2022, the Company announced that its Board of Directors is evaluating a full range of potential strategic
alternatives to maximize shareholder value, including financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. Certain potential strategic transaction alternatives could result in
substantial dilution to existing stockholders and have a material adverse effect on the market price of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
potential proceeds from this offering alone will be insufficient for the Company&#146;s long-term financing needs, and management has implemented, and may implement more stringent, cost reduction and other cash-focused measures to manage liquidity.
Such measures, coupled with the ongoing evaluation process, may result in negative publicity that could impact relationships with employees and commercial third-parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Board of Directors&#146; evaluation process will result in a transaction, or if such a transaction is
consummated, that it will successfully enhance stockholder value. If a strategic transaction is insufficient to address the Company&#146;s long-term financing needs, the Company will need to significantly delay or further scale back operations or
potentially cease operations, in part or in full. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares of common stock Calyxt will issue under the Sales Agreement at any
one time or in total is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has not committed to sell any specific number of shares of common stock under the Sales
Agreement. The number of shares of common stock that are sold in this offering will be determined by Calyxt during the pendency of the Sales Agreement based on, among other things, market conditions and the market price of Calyxt&#146;s common
stock. Accordingly, it is not possible to predict the number of shares of common stock that will ultimately be issued under the Sales Agreement, if any common stock is issued thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt&#146;s management will have broad discretion over the use of the proceeds Calyxt receives in this offering and might not apply the proceeds in
ways that increase the value of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s management will have broad discretion to use the net proceeds from
this offering, and you will be relying on the judgment of Calyxt&#146;s management regarding the application of these proceeds. You will not have the opportunity to influence Calyxt&#146;s decisions on how to use the proceeds, and Calyxt may not
apply the net proceeds of this offering in ways that increase the value of your investment. Because of the number and variability of factors that will determine Calyxt&#146;s use of the net proceeds from this offering, their ultimate use may vary
substantially from their currently intended use. The failure by Calyxt&#146;s management to apply these funds effectively could harm Calyxt&#146;s business. Pending their use, Calyxt intends to invest the net proceeds from this offering in
marketable securities that may include investment-grade interest-bearing securities, money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government in accordance with Calyxt&#146;s investment
policy. These investments may not yield a favorable return to Calyxt&#146;s stockholders. If Calyxt does not invest or apply the net proceeds from this offering in ways that enhance stockholder value, Calyxt may fail to achieve expected financial
results, which could cause its stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of Calyxt&#146;s common stock has been and could remain volatile, which
could adversely affect the market price of Calyxt&#146;s common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Calyxt&#146;s common stock has
experienced, and may continue to experience, volatility in response to various factors. Between January&nbsp;1, 2022, and September&nbsp;30, 2022, the closing price of Calyxt&#146;s common stock on the Nasdaq Global Market fluctuated from a high of
$2.46 per share to a low of $0.17 per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share. Some factors that may cause the market price of Calyxt&#146;s common stock to fluctuate include Calyxt&#146;s quarterly operating results, Calyxt&#146;s perceived prospects or the
perceptions of the market of Calyxt&#146;s pipeline, new products or technologies, changes in securities analysts&#146; recommendations or earnings estimates and Calyxt&#146;s ability to meet such estimates, changes in general conditions in the
economy or the financial markets, capital raising activity and other developments affecting Calyxt, its competitors or Cellectis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
and other market and industry factors may cause the market price and demand for Calyxt&#146;s common stock to fluctuate substantially, regardless of Calyxt&#146;s actual operating performance, which may limit or prevent investors from readily
selling their common stock at a favorable price or at all and may otherwise negatively affect the liquidity of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
common stock offered hereby will be sold at other than fixed prices, and investors who buy shares of common stock at different times will likely pay different prices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the sales of common stock offered hereby will be made at other than fixed prices from time to time, the prices at which Calyxt sells
these shares of common stock will vary and these variations may be significant. Investors who participate in this offering at different times will likely pay different prices. Calyxt will have discretion, subject to market demand, to vary the
timing, prices, and numbers of shares sold, and there is no minimum or maximum sale price. Investors may experience a decline in the value of their investment as a result of sales made at prices lower than the prices they paid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of Calyxt&#146;s common stock by Cellectis or others, or the perception that such sales may occur, could depress the market price of
Calyxt&#146;s common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2022, Cellectis owned 51.3&nbsp;percent of Calyxt&#146;s outstanding shares of
common stock. Future sales of these shares in the public market will be subject to the volume and other restrictions of Rule 144 under the Securities Act for so long as Cellectis is deemed to be Calyxt&#146;s affiliate, unless the shares to be sold
are registered with the SEC. Cellectis is entitled to various rights with respect to the registration of its shares under the Securities Act pursuant to the Stockholders Agreement. Registration of these shares under the Securities Act would result
in these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration statement. In addition, the issuance of the shares of Calyxt common stock issuable upon exercise of the
outstanding Common Warrants has been registered under the Securities Act and such upon issuance, such shares of Calyxt common stock will be freely tradable without restriction under the Securities Act. Calyxt is unable to predict with certainty
whether or when Cellectis will sell a substantial number of shares of Calyxt&#146;s common stock or whether or when any Common Warrants will be exercised. The sale by Cellectis of a substantial number of shares or the exercise of Common Warrants and
the shares of Calyxt&#146;s common stock issued upon their exercise, or a perception that such sales could occur, could significantly reduce the market price of Calyxt&#146;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt has in the past failed to satisfy certain continued listing requirements of the Nasdaq Global Market and could fail to satisfy those requirements
again in the future which could affect the market price of Calyxt&#146;s common stock and liquidity and reduce its ability to raise capital. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, Calyxt&#146;s common stock trades on the Nasdaq Global Market. In May 2022, Calyxt received a notification from Nasdaq informing it
that the closing bid price for Calyxt&#146;s common stock had been below $1.00 for 30 consecutive business days and that the Company, therefore, was not in compliance with the bid price requirements for continued listing on the Nasdaq Global Market.
At Calyxt&#146;s 2022 annual meeting, Calyxt&#146;s stockholders approved a reverse stock split that, if effected, could cure this deficiency. However, there can be no assurance that Calyxt will be able to implement the reverse stock split and cure
this deficiency, or if Calyxt does cure this deficiency, that it will not fall out of compliance again in the future. If Calyxt fails to maintain compliance with any Nasdaq listing requirements, Calyxt could be delisted and its stock would be
considered a penny stock under regulations of the SEC, and would therefore be subject to rules that impose additional sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
practice requirements on broker-dealers who sell Calyxt&#146;s securities. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting
transactions in Calyxt&#146;s common stock, which could severely limit the market liquidity of Calyxt&#146;s common stock and your ability to sell its securities in the secondary market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt&#146;s ability to use its net operating losses to offset future taxable income may be subject to certain limitations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, Calyxt had approximately $228.5&nbsp;million of net operating losses, or NOLs, for federal and state income tax
purposes, which may be available to offset federal income tax liabilities in the future. In addition, Calyxt may generate additional NOLs in future years. Calyxt has established a full valuation allowance for its deferred tax assets, including NOLs,
due to the uncertainty that enough taxable income will be generated to utilize the assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s ability to utilize its NOLs may
be limited if it experiences an &#147;ownership change&#148; as defined in Section&nbsp;382 (&#147;Section&nbsp;382&#148;) of the Internal Revenue Code of 1986, as amended. An ownership change generally occurs if certain direct or indirect 5%
shareholders increase their aggregate percentage ownership of a corporation&#146;s stock by more than 50 percentage points over their lowest percentage ownership at any time during the testing period, which is generally the three-year period
preceding any potential ownership change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that Calyxt will not experience a current or future ownership change
under Section&nbsp;382 that would significantly limit or possibly eliminate its ability to use its NOLs. Current or potential future transactions by Calyxt involving the sale or issuance of Calyxt&#146;s common stock, or the exercise of Common
Warrants, including pursuant to this offering, or a combination of such transactions, may result in ownership changes under Section&nbsp;382. In addition, Calyxt may experience ownership changes as a result of shifts in the direct or indirect
ownership of its stock, some of which may be outside of its control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382, a current or future ownership change would
subject Calyxt to an annual limitation that applies to the amount of <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs that may be used to offset post-ownership change taxable income. This limitation is generally determined by
multiplying the value of a corporation&#146;s stock immediately before the ownership change by the applicable long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate. Any unused annual limitation may, subject to certain limits, be carried
over to later years, and the limitation may under certain circumstances be increased by <FONT STYLE="white-space:nowrap">built-in</FONT> gains in the assets held by such corporation at the time of the ownership change. This limitation could cause
Calyxt&#146;s U.S. federal income taxes to be greater, or to be paid earlier, than they otherwise would be, and could cause some of Calyxt&#146;s NOLs to expire unused. Similar rules and limitations may apply for state income tax purposes. There is
also a risk that future legal or regulatory changes may limit Calyxt&#146;s ability to use current or future NOLs to offset Calyxt&#146;s future federal income tax liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the documents incorporated herein contain &#147;forward-looking statements&#148; within the meaning of
the federal securities laws, including Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has made
these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &#147;anticipates,&#148;
&#147;believes,&#148; &#147;continue,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plans,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;targets,&#148;
&#147;will,&#148; or the negative of these terms and other similar terminology. Forward-looking statements in this prospectus and the documents incorporated herein include statements about the Company&#146;s future financial performance, including
its cash runway; Calyxt&#146;s product pipeline and development; the Company&#146;s business model and strategies for the development, commercialization and sales of commercial products; commercial demand for its synthetic biology solutions; the
development and deployment of its PlantSpring technology platform; its ability to deploy and leverage its artificial intelligence and machine learning (&#147;AIML&#148;) capabilities; the ability to scale production capability for its BioFactory
production system; potential development agreements, partnerships, customer relationships, and licensing arrangements and their contribution to the Company&#146;s financial results, cash usage, and growth strategies; the potential impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s business and operating results; and anticipated trends in its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other forward-looking statements are predictions and projections about future events and trends based on Calyxt&#146;s current
expectations, objectives, and intentions and are premised on current assumptions. Calyxt&#146;s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by
forward-looking statements due to a variety of factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of increased competition, including competition from a broader array of synthetic biology companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition for customers, partners, and licensees and the successful execution of development and licensing
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at its key facilities, including disruptions impacting its BioFactory production system;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">flaws in AIML algorithms, insufficiency of data inputs required by such algorithms, and human error in
interacting with AIML; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in customer preferences and market acceptance of its products; changes in market consensus as to what
attributes are required for a product to be considered &#147;sustainable&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of adverse events during development, including unsuccessful pilot production of plant-based
chemistries or field trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of improper handling of its product candidates during development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failures by third-party contractors; inaccurate demand forecasting or milestone and royalty payment projections;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of commercialization efforts by commercial partners or licensees; disruptions to supply chains,
including raw material inputs for its BioFactory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of changes or increases in oversight and regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or challenges regarding intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proliferation and continuous evolution of new technologies; management changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dislocations in the capital markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity and duration of the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the
resulting impact on macro-economic conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any adverse impact of our pursuit of strategic alternatives on ongoing negotiations with potential customers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not we are able to identify and consummate an attractive strategic alternative pursuant to our ongoing
exploration of such transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other important factors discussed under the heading &#147;Risk Factors&#148; in Calyxt&#146;s filings with the
Securities and Exchange Commission (&#147;SEC&#148;), included in Part I, Item 1.A. of Calyxt&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, which is incorporated by reference
herein, and Calyxt&#146;s subsequent reports on Forms <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all
potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Any of these factors, in whole or in part, could materially and adversely affect Calyxt&#146;s
business, financial condition, results of operations and the price of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statement made by
Calyxt in this prospectus supplement and the documents incorporated by reference herein or therein is based only on information currently available to Calyxt and speaks only as of the date of this prospectus supplement or such incorporated document,
as the case may be. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements after the date of the document in which such statement appears, whether as a result of new information, future
developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should
read this prospectus supplement together with the documents Calyxt has filed with the SEC that are incorporated by reference and any free writing prospectus that the Company may authorize for use in connection with this offering completely and with
the understanding that Calyxt&#146;s actual future results may be materially different from what Calyxt currently expects. Calyxt qualifies all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of proceeds from this offering will depend upon the number of shares of Calyxt&#146;s common stock sold and the market price at
which such shares are sold. There can be no assurance that Calyxt will sell any shares under or fully utilize the Sales Agreement as a source of financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt currently intends to use the net proceeds from the sale of the shares of its common stock offered hereunder for working capital and
general corporate purposes. Calyxt has not determined the amounts that it plans to spend on any specific area or the timing of such expenditures. Accordingly, Calyxt&#146;s management will have broad discretion to use the net proceeds from this
offering. Pending Calyxt&#146;s use of the net proceeds from this offering, Calyxt intends to invest the net proceeds in marketable securities that may include investment-grade interest-bearing securities, money market accounts, certificates of
deposit, commercial paper and guaranteed obligations of the U.S. government in accordance with Calyxt&#146;s investment policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a description of the material terms and provisions of Calyxt&#146;s amended and restated certificate of incorporation (the
&#147;Certificate of Incorporation&#148;) and Calyxt&#146;s amended and restated bylaws <FONT STYLE="white-space:nowrap">(&#147;By-laws&#148;)</FONT> as well as relevant terms and provisions of Calyxt&#146;s indemnification agreements for directors
and officers and Delaware law affecting the rights of Calyxt&#146;s stockholders. This summary does not purport to be complete and is qualified in its entirety by the provisions of Calyxt&#146;s Certificate of Incorporation, <FONT
STYLE="white-space:nowrap">By-laws</FONT> and such indemnification agreements. Copies of Calyxt&#146;s Certificate of Incorporation, <FONT STYLE="white-space:nowrap">By-laws</FONT> and indemnification agreements have been filed with the SEC and are
incorporated by reference into the registration statement of which this prospectus supplement forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s authorized capital stock consists of 275,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of
preferred stock, par value $0.0001 per share. The only equity securities currently outstanding are shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2022, there were 46,715,542 shares of common stock issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> The holders of Calyxt&#146;s common stock are entitled to one vote per share on all matters to be voted upon by the
stockholders. Holders of Calyxt&#146;s common stock do not have cumulative voting rights in the election of directors. Accordingly, the holders of a majority of the voting power of Calyxt&#146;s common stock could, if they so choose, elect all the
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights.</I> Holders of common stock are entitled to receive dividends if, as and when declared by Calyxt&#146;s
Board of Directors, out of Calyxt&#146;s legally available assets, in cash, property or shares of Calyxt&#146;s capital stock, after payments of dividends required to be paid on outstanding preferred stock, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Distributions in Connection with Mergers or Other Business Combinations.</I> Upon a merger, consolidation or substantially similar
transaction, holders of common stock will be entitled to receive equal per share payments or distributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights.</I>
Upon Calyxt&#146;s liquidation, dissolution or winding up, any business combination or a sale or disposition of all or substantially all of Calyxt&#146;s assets, the assets legally available for distribution to Calyxt&#146;s stockholders will be
distributable ratably among the holders of the common stock, subject to prior satisfaction of all outstanding debts and other liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholders Agreement.</I> In connection with Calyxt&#146;s IPO, Calyxt entered into a stockholders agreement dated July&nbsp;25,
2017 with Cellectis (as amended from time to time, the &#147;Stockholders Agreement&#148;), pursuant to which Cellectis has certain specified rights. Pursuant to the Stockholders Agreement, for so long as Cellectis beneficially owns at least 50% of
the then-outstanding shares of Calyxt&#146;s shares of Common Stock, Cellectis has certain rights, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any modification to Calyxt&#146;s or any future subsidiary&#146;s share capital (e.g., share capital
increase or decrease), the creation of any subsidiary, any grant of stock-based compensation, any distributions or initial public offering, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> liquidation, winding up or <FONT
STYLE="white-space:nowrap">carve-out</FONT> transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve Calyxt&#146;s annual business plan and annual budget and any modification thereto;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any external growth transactions exceeding $500,000 and not included in the approved annual business
plan and annual budget; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any investment and disposition decisions exceeding $500,000 and not included in the approved annual
business plan and annual budget (excluding the purchase and sale of inventory as a part of the normal course of business); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any related-party agreement and any agreement or transaction between the executives or stockholders of
Calyxt, on the one hand, and Calyxt or any of its subsidiaries, on the other hand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any decision pertaining to the recruitment, dismissal/removal, or increase of the compensation of
executives and corporate officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any material decision relating to a material litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any decision relating to the opening of a social or restructuring plan or <FONT
STYLE="white-space:nowrap">pre-insolvency</FONT> proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any buyback by Calyxt of its own shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any new borrowings or debts exceeding $500,000 and early repayment of loans, if any (it being
understood that Cellectis will approve the entering into of contracts for revolving loans and other short-term loans and the repayment of such for financing general operating activities, such as revolving loans for inventory or factoring of
receivables); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve grants of any pledges on securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to develop new activities and businesses not described in the annual business plan and annual budget;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve entry into any material agreement or partnership; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any offshore and relocation activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cellectis has the following rights for so long as it beneficially owns at least 15% of the then outstanding shares of
Calyxt&#146;s common stock, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to nominate the greater of three members of Calyxt&#146;s Board of Directors or a majority of the directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to designate the Chairman of Calyxt&#146;s Board of Directors and one member to each of the audit committee of
the Board of Directors, the compensation committee of the Board of Directors and the nominating and corporation governance committee of the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any amendments to Calyxt&#146;s Certificate of Incorporation or
<FONT STYLE="white-space:nowrap">By-laws</FONT> that would change the name of the company, its jurisdiction of incorporation, the location of its principal executive offices, the purpose or purposes for which Calyxt is incorporated or the Cellectis
approval items set forth in the stockholders agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the payment of any regular or special dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the commencement of any proceeding for the voluntary dissolution, winding up or bankruptcy of Calyxt
or a material subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any public or private offering, merger, amalgamation or consolidation of us or the spinoff of a
business of Calyxt&#146;s or any sale, conveyance, transfer or other disposition of Calyxt&#146;s assets; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any change to Calyxt&#146;s Board of Directors contrary to the stockholders agreement or the
Company&#146;s Certificate of Incorporation or <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Matters.</I>
Calyxt&#146;s Certificate of Incorporation does not entitle holders of Calyxt&#146;s common stock to preemptive rights. No redemption or sinking fund provisions apply to Calyxt&#146;s common stock. The rights, preferences and privileges of holders
of Calyxt&#146;s common stock are subject to, and may be adversely affected by, the rights of holders of any series of preferred stock that Calyxt may designate in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Certificate of Incorporation authorizes its Board of Directors, without further action by the stockholders (unless so required by
applicable law or Nasdaq listing standards), to issue preferred stock in one or more series, to increase or decrease the number of shares of any series subsequent to the issuance of that series, but not below the number of shares of such series then
outstanding, and to determine the preferences, limitations and rights of any shares of preferred stock that Calyxt chooses to issue, without vote or action by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will fix the designations, powers, preferences and relative, participating, optional or other rights, if any, of the preferred stock of
each such series, as well as any qualifications, limitations or restrictions thereon, in the certificate of designation relating to that series. Calyxt will file as an exhibit to the registration statement of which this prospectus supplement is a
part, or will incorporate by reference from reports that Calyxt files with the SEC, the form of any certificate of designation that sets forth the terms of the series of preferred stock Calyxt is offering before the issuance of that series of
preferred stock. If Calyxt offers preferred stock, the terms of the particular series of preferred stock will be described in the applicable prospectus supplement. This description will include (to the extent applicable): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the applicable series number of shares of such series Calyxt is offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, period and payment date and method of calculation for dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on Calyxt&#146;s ability to
exercise those redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into Calyxt&#146;s common stock or any other security of the
Company, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable for Calyxt&#146;s common stock or any other security of the
Company, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material United States federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if Calyxt
liquidates, dissolves or winds up its affairs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with
the series of preferred stock as to dividend rights and rights if Calyxt liquidates, dissolves or winds up its affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law (the &#147;DGCL&#148;) provides that the holders of preferred stock will have the
right to vote separately as a class (or, in some cases, as a series) on an amendment to Calyxt&#146;s Certificate of Incorporation if the amendment would change the par value, the number of authorized shares of the class or the powers, preferences
or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Board of Directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of Calyxt&#146;s common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the
effect of delaying, deferring or preventing a change in control of Calyxt and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. Additionally, the issuance of preferred stock may
have the effect of decreasing the market price of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Anti-Takeover Law and Provisions of Calyxt&#146;s Charter and
Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provisions may make a change in control of Calyxt&#146;s business more difficult and could delay, defer or
prevent a tender offer or other takeover attempt that a stockholder might consider to be in its best interest, including takeover attempts that might result in the payment of a premium to stockholders over the market price for their shares. These
provisions also may promote the continuity of Calyxt&#146;s management by making it more difficult for a person to remove or change the incumbent members of Calyxt&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized but Unissued Shares; Undesignated Preferred Stock.</I> The authorized but unissued shares of Calyxt&#146;s common stock will be
available for future issuance without stockholder approval. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions and employee benefit plans. In addition,
Calyxt&#146;s Board of Directors may authorize, without stockholder approval, the issuance of undesignated preferred stock with voting rights or other rights or preferences designated from time to time by Calyxt&#146;s Board of Directors. The
existence of authorized but unissued shares of common stock or preferred stock may enable Calyxt&#146;s Board of Directors to render more difficult or to discourage an attempt to obtain control of Calyxt by means of a merger, tender offer, proxy
contest or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Election and Removal of Directors.</I> Calyxt&#146;s Board of Directors consists of not less than five nor more
than eleven directors, excluding any directors elected by holders of preferred stock pursuant to provisions of any applicable series of preferred stock entitling the holders thereof to separately elect directors. The exact number of directors will
be fixed from time to time by resolution of Calyxt&#146;s Board of Directors. As of the date of this prospectus supplement, Calyxt&#146;s Board of Directors has eight members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholders Agreement, Cellectis has the right to nominate the greater of three directors or a majority of directors to
Calyxt&#146;s Board of Directors so long as it continues to own at least 15% of the then-outstanding shares of Calyxt&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after Cellectis beneficially owns less than 50% of Calyxt&#146;s then outstanding common stock, Calyxt&#146;s Certificate of
Incorporation provides that directors may be removed only for cause and only by the affirmative vote of holders of a majority of Calyxt&#146;s then outstanding stock. Prior to such time, directors may be removed with or without cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Classified Board of Directors.</I> Calyxt&#146;s Board of Directors currently is not
classified. However, Calyxt&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> provide that Calyxt&#146;s Board of Directors will be classified with approximately <FONT STYLE="white-space:nowrap">one-third</FONT>
of the directors elected each year at such time as Cellectis no longer holds at least 50% of Calyxt&#146;s then outstanding common stock. The number of directors will be fixed from time to time by a majority of the total number of directors that
Calyxt would have at the time such number is fixed if there were no vacancies. The directors will be divided into three classes, designated class I, class II and class III. Each class will consist, as nearly as may be possible, of <FONT
STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting the entire Board of Directors. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be
elected for a three-year term and until their successors are duly elected and qualified. In addition, if the number of directors is changed, any increase or decrease will be apportioned by Calyxt&#146;s Board of Directors among the classes so as to
maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class or from the removal from office, death, disability, resignation
or disqualification of a director or other cause will hold office for a term that will coincide with the remaining term of that class, but in no case will a decrease in the number of directors have the effect of removing or shortening the term of
any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Director Vacancies.</I> Calyxt&#146;s Certificate of Incorporation authorizes only its Board of Directors to
fill vacant directorships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>No Cumulative Voting.</I> Calyxt&#146;s Certificate of Incorporation provides that stockholders do not have
the right to cumulate votes in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Special Meetings of Stockholders</I>. At any time after Cellectis
beneficially owns less than 50% of Calyxt&#146;s then outstanding common stock, Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> and Certificate of Incorporation provide that special meetings of its stockholders may only be called by
the Board of Directors. Prior to such time, a special meeting may also be called by the secretary of the Company at the request of stockholders holding a majority of the outstanding shares entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance Notice Procedures for Director Nominations.</I> Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> establish advance
notice procedures for stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders. Although Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> do not give the Board of Directors
the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the <FONT STYLE="white-space:nowrap">By-laws</FONT> may have the effect of precluding the conduct of certain business at a meeting if the
proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Action by Written Consent.</I> At any time after Cellectis beneficially owns less than 50% of Calyxt&#146;s then outstanding common stock,
Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> and Certificate of Incorporation provide that any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders
and may not be effected by any consent in writing in lieu of a meeting of such stockholders, subject to the rights of the holders of any series of preferred stock. Prior to such time, such actions may be taken without a meeting by written consent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amending Calyxt&#146;s Certificate of Incorporation and Bylaws.</I> At any time after Cellectis beneficially owns less than 50% of
Calyxt&#146;s then outstanding common stock, Calyxt&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended by the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of Calyxt&#146;s common stock. Prior to such time, Calyxt&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended by the affirmative vote of the
holders of a majority of the voting power of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusive Jurisdiction.</I> Calyxt&#146;s Certificate of
Incorporation provides that, unless it consents to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on Calyxt&#146;s behalf,
any action asserting a claim of breach of fiduciary duty owed by any of the Company&#146;s directors, officers, or other employees to Calyxt or to its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders, any action asserting a claim arising pursuant to the DGCL, or any action asserting a claim governed by the internal affairs doctrine. Notwithstanding the foregoing, because the
Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce duties or liabilities created by the Exchange Act or the rules and regulations thereunder, the exclusive forum provision does not apply to any action arising under
the Exchange Act. Although the exclusive forum provision applies, to the extent permitted by law, to Securities Act claims, the Securities Act creates concurrent federal and state jurisdiction over suits brought to enforce duties or liabilities
created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce this exclusive forum provision with respect to a Securities Act claim. Neither Calyxt nor its stockholders
may waive compliance with the federal securities laws or the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Business Combinations with Interested
Stockholders.</I> Subject to certain exceptions, Section&nbsp;203 of the DGCL prohibits a public Delaware corporation from engaging in a business combination (as defined in such section) with an &#147;interested stockholder&#148; (defined generally
as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder,
unless (i)&nbsp;prior to such time the Board of Directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii)&nbsp;upon consummation of the
transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the
voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (A)&nbsp;by persons who are directors and also officers of such corporation and (B)&nbsp;by employee stock
plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii)&nbsp;at or subsequent to such time the business combination is
approved by the Board of Directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the
interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original
certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. Calyxt has expressly elected not to be
governed by the &#147;business combination&#148; provisions of Section&nbsp;203 of the DGCL until after such time as Cellectis no longer beneficially owns at least 50% of Calyxt&#146;s common stock. At that time, such election shall be automatically
withdrawn and Calyxt will thereafter be governed by the &#147;business combination&#148; provisions of Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of
Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are
presented to the corporation or its officers, directors or stockholders. Calyxt&#146;s Certificate of Incorporation renounces, to the maximum extent permitted from time to time by Delaware law, any interest or expectancy that Calyxt has in, or right
to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to Calyxt&#146;s officers, directors or stockholders or their respective affiliates, other than those officers, directors,
stockholders or affiliates who are Calyxt&#146;s or its subsidiaries&#146; employees. Calyxt&#146;s Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Cellectis or any of its affiliates or any director who is
not employed by Calyxt, or his or her affiliates has any duty to refrain from (i)&nbsp;engaging in a corporate opportunity in the same or similar lines of business in which Calyxt or its subsidiaries now engage or propose to engage or
(ii)&nbsp;otherwise competing with Calyxt or its subsidiaries. In addition, to the fullest extent permitted by law, in the event that Cellectis or any <FONT STYLE="white-space:nowrap">non-employee</FONT> director acquires knowledge of a potential
transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for Calyxt or its affiliates, such person has no duty to communicate or offer such transaction or business opportunity
to Calyxt or any of its affiliates and they </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may take any such opportunity for themselves or offer it to another person or entity. Calyxt&#146;s Certificate of Incorporation does not renounce its interest in any business opportunity that is
expressly offered to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director solely in his or her capacity as a director of Calyxt. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate
opportunity for Calyxt unless Calyxt would be permitted to undertake the opportunity under its Certificate of Incorporation, Calyxt has sufficient financial resources to undertake the opportunity and the opportunity would be in line with
Calyxt&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholders Agreement provides Cellectis with certain registration rights, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration</I>&#151;Cellectis may request that Calyxt register for resale all or a portion of their shares. Any such request must
cover a quantity of shares with an anticipated aggregate offering price of at least $25.0&nbsp;million. To the extent Calyxt is a well-known seasoned issuer, Cellectis may also request that Calyxt file an automatic shelf registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> that covers the registrable securities requested to be registered. Depending on certain conditions, Calyxt may defer a demand registration for up to 90 days in any twelve month period. Cellectis will
agree pursuant to a contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> not to exercise any of its rights under the registration rights agreement during a <FONT STYLE="white-space:nowrap">90-day</FONT> restricted period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights</I>&#151;In the event that Calyxt proposes to register any of its securities under the Securities Act of
1933, either for its own account or for the account of its other security holders, Cellectis is entitled to certain piggyback registration rights allowing it to include its shares in the registration, subject to certain marketing and other
limitations. As a result, whenever Calyxt proposes to file a registration statement under the Securities Act, Cellectis is entitled to notice of the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expenses; Indemnification</I>&#151;The registration rights provides that Calyxt must pay all registration expenses (other than the
underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The registration rights contain customary indemnification and contribution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term</I>&#151;The registration rights will remain in effect with respect to any shares covered by the Stockholders Agreement until
(i)&nbsp;all of Cellectis&#146; shares have been sold pursuant to an effective registration statement under the Securities Act; (ii)&nbsp;all of Cellectis&#146; shares have been sold to the public pursuant to Rule 144 under the Securities Act; or
(iii)&nbsp;Cellectis owns less than 10% of the then outstanding shares of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification and Limitations on
Directors&#146; Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL grants each Delaware corporation the power to indemnify any person who is or
was a director, officer, employee or agent of a corporation, against expenses, including attorneys&#146; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of serving or having served in any such capacity, if he or she acted in good
faith in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A Delaware
corporation may similarly indemnify any such person in actions by or in the right of the corporation if he or she acted in good faith in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no
indemnification may be made in respect of any claim, issue or matter as to which the person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the court in which the action
was brought determines that, despite adjudication of liability, but in view of all of the circumstances of the case, the person is fairly and reasonably entitled to indemnity for expenses which the Delaware Court of Chancery or other court shall
deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL enables a corporation in its certificate of
incorporation, or an amendment thereto, to eliminate or limit the personal liability of a director to the corporation or its stockholders for monetary damages for violations of the director&#146;s fiduciary duty as a director, except (i)&nbsp;for
any breach of the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;pursuant to
Section&nbsp;174 of the DGCL (providing for director liability with respect to unlawful payment of dividends or unlawful stock purchases or redemptions) or (iv)&nbsp;for any transaction from which a director derived an improper personal benefit.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Certificate of Incorporation indemnifies its directors and principal officers to the fullest extent permitted by Delaware
law and Calyxt&#146;s Certificate of Incorporation also allows Calyxt&#146;s Board of Directors to indemnify other employees. This indemnification extends to the payment of judgments in actions against officers and directors and to reimbursement of
amounts paid in settlement of such claims or actions and may apply to judgments in favor of the corporation or amounts paid in settlement to the corporation. This indemnification also extends to the payment of attorneys&#146; fees and expenses of
principal officers and directors in suits against them where the officer or director acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, Calyxt&#146;s best interests, and, with respect to any criminal
action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. This right of indemnification is not exclusive of any right to which the officer or director may be entitled as a matter of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s directors and officers are insured pursuant to a &#147;directors and officers&#148; insurance policy, which provides protection
against <FONT STYLE="white-space:nowrap">un-indemnified</FONT> losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for losses incurred by Calyxt in response to securities claims involving
directors and officers. The policy contains various customary exclusions for policies of this type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Calyxt&#146;s Board of
Directors has adopted a policy to enter into an indemnification agreement with each of its directors and officers, which provide for certain advancement and indemnification rights. Each indemnification agreement provides, subject to certain
exceptions, to indemnify and hold harmless the director or officer to the fullest extent permitted by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any
indemnification available to directors affiliated with Cellectis, Calyxt has agreed (i)&nbsp;that it is the indemnitor of first resort with respect to any amounts incurred or sustained in connection with such person&#146;s role as a director of
Calyxt, (ii)&nbsp;that it will be responsible for, and required to advance, the full amount of such amounts without regard to any rights such person may have, or be pursuing, against Cellectis, and (iii)&nbsp;to irrevocably waive, relinquish and
release Cellectis from any and all claims for contribution, subrogation or any other recovery in respect of such amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt believes
that the limitation of liability and indemnification provisions in its Certificate of Incorporation, <FONT STYLE="white-space:nowrap">By-laws,</FONT> indemnification agreements and insurance policies are necessary to attract and retain qualified
directors and officers. However, these provisions may discourage derivative litigation against directors and officers, even though an action, if successful, might benefit Calyxt and its stockholders. Furthermore, a stockholder&#146;s investment may
be adversely affected to the extent Calyxt pays the costs of settlement and damage awards against directors and officers as required or allowed by these limitations of liability and indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of Calyxt&#146;s directors, officers, employees or agents as to which
indemnification is sought from Calyxt, nor is the Company aware of any threatened litigation or proceeding that may result in an indemnification claim. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s shares of common
stock are listed on the Nasdaq Global Market under the symbol &#147;CLXT.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for Calyxt&#146;s common stock is Broadridge Corporate Issuer Solutions, Inc., 1155 Long Island Avenue,
Edgewood, NY 11717. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_8"></A>DILUTION </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s net tangible book value as of June&nbsp;30, 2022, was $13,759,000, or $0.29 per share. Net tangible book value per share is
determined by dividing Calyxt&#146;s total tangible assets, less total liabilities, by the number of shares of Calyxt&#146;s common stock outstanding as of June&nbsp;30, 2022. Dilution with respect to net tangible book value per share represents the
difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of Calyxt&#146;s common stock immediately after this offering. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of 15,661,000 shares of Calyxt&#146;s common stock in the aggregate amount of approximately $2.7&nbsp;million
in this offering at an assumed offering price of $0.17, the last reported sale price of Calyxt&#146;s common stock on the Nasdaq Global Market on September&nbsp;30, 2022, and after deducting commissions and estimated aggregate offering expenses
payable by Calyxt, Calyxt&#146;s as adjusted net tangible book value as of June&nbsp;30, 2022, would have been approximately $16,041,499, or $0.26 per share. This represents an immediate decrease in net tangible book value of $0.04 per share to
existing stockholders and immediate accretion in net tangible book value of $(0.09) per share to new investors purchasing Calyxt&#146;s common stock in this offering. The following table illustrates this accretion on a per share basis: </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of June&nbsp;30, 2022, after giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution (accretion) per share to investors purchasing shares of Calyxt&#146;s common stock in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after this offering is based on 46,715,542 shares
outstanding as of June&nbsp;30, 2022, and excludes as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,937,988 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average
exercise price of $7.30 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,406,042 shares of common stock issuable upon the vesting and settlement of restricted stock units outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,130,000 shares of common stock issuable upon the vesting and settlement of performance stock units outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,961,677 shares of common stock reserved for future issuance under Calyxt&#146;s 2017 Omnibus Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,760,000 shares of common stock issuable upon exercise of outstanding Common Warrants, each with an exercise
price of $1.41 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above illustration of dilution per share to investors participating in this offering
assumes no exercise of outstanding Common Warrants, no further exercise of outstanding options and no further issuance of shares upon vesting of outstanding restricted stock units or performance units. To the extent that any outstanding options or
Common Warrants are exercised or other shares are issued upon vesting of outstanding awards or otherwise, there will be further dilution to new investors. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of shares of Calyxt&#146;s common stock, if any, under this prospectus supplement may be made in sales deemed to be an &#147;at the
market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act from time to time and, therefore, the price of any such securities sold may vary. An increase of $1.00 per share in the price at which the shares of common stock
are sold from the assumed offering price of $0.17 per share shown in the table above, assuming all 15,661,000 shares of Calyxt&#146;s common stock offered hereby is sold during the term of the Sales Agreement at that price of $1.17 per share, would
increase Calyxt&#146;s as adjusted net tangible book value per share after the offering to $0.50 per share, which would represent a decrease in net tangible book value per share to new investors in this offering of $0.67 per share, after deducting
commissions and estimated offering expenses payable by Calyxt. This information is supplied for illustrative purposes only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has entered into the Sales Agreement, under which it may offer and sell up to 15,661,000 shares of common stock from time to time
through Jefferies acting as agent. Sales of Calyxt&#146;s shares of common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that is deemed to be an &#147;at the market offering&#148; as
defined in Rule 415(a)(4) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time Calyxt wishes to issue and sell shares of its common stock under the Sales
Agreement, it will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be
made. Once Calyxt has so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares
up to the amount specified on such terms. The obligations of Jefferies under the Sales Agreement to sell shares of Calyxt&#146;s common stock are subject to a number of conditions that Calyxt must meet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The settlement of sales of shares between Calyxt and Jefferies is generally anticipated to occur on the second trading day following the date
on which the sale was made. Sales of shares of Calyxt&#146;s common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as Calyxt and Jefferies may agree
upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will pay Jefferies a commission
equal to 3.0% of the aggregate gross proceeds it receives from each sale of shares of Calyxt&#146;s common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount,
commissions and proceeds to Calyxt, if any, are not determinable at this time. In addition, subject to certain exceptions, Calyxt has agreed to reimburse Jefferies for the fees and disbursements of its counsel, payable upon execution of the Sales
Agreement, in an amount not to exceed $75,000, in addition to certain ongoing disbursements of its legal counsel payable in the amount of up to $25,000 in connection with each diligence bring-down thereafter. Calyxt estimates that the total expenses
for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the terms of the Sales Agreement, will be approximately $0.3&nbsp;million. The remaining sale proceeds, after deducting any other transaction fees, will
equal Calyxt&#146;s net proceeds from the sale of such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jefferies will provide written confirmation to Calyxt before the open on
the Nasdaq Global Market on the day following each day on which Calyxt&#146;s shares of common stock are sold under the Sales Agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales
and the proceeds to Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of Calyxt&#146;s shares of common stock on Calyxt&#146;s behalf, Jefferies will
be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. Calyxt has agreed to indemnify Jefferies against certain civil
liabilities, including liabilities under the Securities Act. Calyxt has also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of shares of Calyxt&#146;s common stock pursuant to the Sales Agreement will terminate upon the earlier of (i)&nbsp;the sale of
all shares of common stock subject to the Sales Agreement and (ii)&nbsp;the termination of the Sales Agreement as permitted therein. Calyxt and Jefferies may each terminate the Sales Agreement at any time upon ten days&#146; prior notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A copy
of the Sales Agreement is filed as an exhibit to the registration statement of which this prospectus supplement forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jefferies and its affiliates may in the future provide various investment banking,
commercial banking, financial advisory and other financial services for Calyxt and its affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade Calyxt&#146;s securities
for its own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies,
and Jefferies may distribute this prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_10"></A>CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the material U.S. federal income tax
considerations related to the acquisition, ownership, and disposition of Calyxt&#146;s common stock acquired pursuant to this offering by <FONT STYLE="white-space:nowrap">a&nbsp;&#147;Non-U.S.&nbsp;Holder,&#148;</FONT> as defined below, that does
not own, and has not owned, actually or constructively, more than 5% of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are <FONT
STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> if for U.S. federal income tax purposes you hold Calyxt&#146;s common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes) and
you are a beneficial owner of Calyxt&#146;s common stock that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual that is not a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation that is not created or organized in or under the laws of the United States, any state thereof, or
the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign estate or trust that in either case is not subject to U.S. federal income tax on <FONT
STYLE="white-space:nowrap">a&nbsp;net-income&nbsp;basis</FONT> on income or gain from Calyxt&#146;s common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
are not <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> if you are a nonresident alien individual present in the United States for 183 days or more in the taxable year of disposition, or if you are a former citizen or former
resident of the United States for U.S. federal income tax purposes. If you are such a person, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership and disposition of Calyxt&#146;s
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances
or to investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;organizations;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;method</FONT></FONT> of accounting for their securities holdings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold Calyxt&#146;s common stock as a position in a hedging transaction, &#147;straddle,&#148;
&#147;conversion transaction,&#148; or other risk reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell Calyxt&#146;s common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">passive foreign investment companies; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a partnership or other pass-through entity (including an entity or arrangement treated as a partnership or other type of
pass-through entity for U.S. federal income tax purposes) that owns Calyxt&#146;s common stock, the U.S. federal income tax treatment of a partner or beneficial owner will generally depend on the status of such partner or beneficial owner and your
activities. Partnerships, partners and beneficial owners in partnerships or other pass-through entities that own Calyxt&#146;s common stock should consult their tax advisors as to the particular U.S. federal income tax considerations applicable to
the acquisition, ownership and disposition of Calyxt&#146;s common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the current provisions of the Code, administrative
pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, changes to any of which subsequent to the date of this prospectus supplement may affect the tax consequences described herein, possibly with retroactive
effect, which may result in tax consequences different from those discussed below. Calyxt has not sought, and will not seek, any ruling from the IRS or any opinion of counsel with respect to the tax considerations discussed herein, and there can be
no assurance that the IRS will not take a position contrary to those discussed below or that any position taken by the IRS will not be sustained. This discussion does not describe all aspects of U.S. federal income taxation that may be relevant to
you in light of your particular circumstances, does not discuss estate, gift, alternative minimum tax or Medicare contribution tax consequences and does not address any aspect of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
taxation. You should consult your tax advisor with regard to the application of the U.S. federal tax laws to your particular situation, as well as any tax consequences arising under the laws of any state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxing jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt does not anticipate declaring or paying any cash dividends to holders of Calyxt&#146;s common stock in the foreseeable future.
Distributions of cash or other property, if any (other than certain distributions of stock), will constitute dividends for U.S. federal income tax purposes to the extent paid from Calyxt&#146;s current or accumulated earnings and profits, as
determined under U.S. federal income tax principles. To the extent those distributions exceed Calyxt&#146;s current and accumulated earnings and profits, they will constitute a return of capital, which will first be applied against and reduce your
basis in Calyxt&#146;s common stock, but not below zero, and then will be treated as gain from the sale or exchange of Calyxt&#146;s common stock and will be treated as described below under &#147;&#151;Gain on Disposition of Calyxt&#146;s Common
Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to you that are not effectively connected with your conduct of a trade or business in the United States
generally will be subject to withholding tax at a 30% rate or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of withholding, you will be required to provide us or Calyxt&#146;s paying agent with a
properly executed applicable <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;or</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN-E</FONT></FONT> (or appropriate successor form), as
applicable, certifying under penalties of perjury that you are not a United States person and you are eligible for the benefits under the applicable tax treaty. These forms may need to be periodically updated. If
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> holds Calyxt&#146;s common stock through a financial institution or other intermediary, <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will be
required to provide the appropriate documentation to the financial institution or other intermediary. <FONT STYLE="white-space:nowrap">A&nbsp;Non-U.S.&nbsp;Holder</FONT> eligible for a reduced rate of U.S. withholding tax pursuant to an income tax
treaty who fails to timely provide an IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN&nbsp;or&nbsp;W-8BEN-E,</FONT></FONT></FONT> as applicable,&nbsp;may obtain a refund of any
excess amounts withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to you are effectively connected with your
conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base maintained by you in the United States), you will generally be taxed on the
dividends in the same manner as a United States person. In this case, you will be exempt from the withholding tax discussed in the preceding paragraph, although you will be required to provide a properly executed
<FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8ECI&nbsp;(or</FONT> appropriate successor form) in order to claim an exemption from withholding. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are
subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates generally applicable to a United States person. Dividends received by a
<FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder</FONT> that are effectively connected with <FONT STYLE="white-space:nowrap">such&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> conduct of a trade or business in the United States (and,
if required by an applicable income tax treaty, attributable to a permanent establishment or fixed base maintained by <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> in the United States) may be subject to an additional branch
profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty). You should consult your tax advisor with respect to other U.S. tax consequences of the acquisition, ownership and disposition of Calyxt&#146;s
common stock, including the possible imposition of the branch profits tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Calyxt&#146;s Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#147;&#151;Information Reporting and Backup Withholding&#148; and &#147;&#151;FATCA,&#148; you
generally will not be subject to U.S. federal income or withholding tax on gain realized on a sale, exchange or other taxable disposition of Calyxt&#146;s common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with your conduct of a trade or business in the United States (and, if required
by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by you in the United States), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calxyt is or has been a &#147;United States real property holding corporation&#148; (&#147;USRPHC&#148;) as
defined in the Code, at any time within the five-year period ending on the date of disposition or your holding period, whichever period is shorter, you are not eligible for an exemption under an applicable income tax treaty, and Calyxt&#146;s common
stock is not regularly traded on an established securities market within the meaning of the applicable Treasury regulations prior to the beginning of the calendar year in which the sale or disposition occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the second bullet point above, a U.S. corporation generally is a USRPHC if the fair market value of its U.S. real property
interests (as defined in the Code and applicable Treasury regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. Although not
free from doubt, Calyxt believes it is not, and does not anticipate becoming, a United States real property holding corporation. If Calyxt is or becomes a USRPHC, subject to the next sentence, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder generally will be taxed on gain recognized on the sale, exchange or other taxable disposition of Calyxt&#146;s common stock in the same manner as if such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a United States person
(subject to an applicable income tax treaty providing otherwise) and/or a 15% withholding tax will apply to the gross proceeds from the sale, exchange or other taxable disposition of Calyxt&#146;s common stock (including a redemption treated as a
sale or exchange for U.S. federal income tax purposes or a distribution treated as a return of capital, as described under &#147;&#151;Distributions&#148; above). However, if and so long as Calyxt&#146;s common stock continues to be &#147;regularly
traded on an established securities market,&#148; as defined by applicable Treasury Regulations, (i)&nbsp;the 15% withholding tax will not apply and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to
U.S. federal income tax with respect to such gain as a result of us being or having been a USRPHC. There can be no assurance that Calyxt&#146;s common stock will be treated as regularly traded on an established securities market for this purpose.
You should consult your tax advisor regarding the possible consequences to you if Calyxt is, or were to become, a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you
recognize gain on a sale or other disposition of Calyxt&#146;s common stock that is effectively connected with your conduct of a trade or business in the United States (and if required by an applicable income tax treaty, is attributable to a
permanent establishment or fixed base maintained by you in the United States), you will generally be subject to U.S. federal income tax at the regular graduated U.S. federal income tax rates generally applicable to a United States person. If you are
a corporation, you may also be subject to the branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. You should consult your tax advisor with respect to other U.S. tax consequences of the
acquisition, ownership and disposition of Calyxt&#146;s common stock, including the possible imposition of the branch profits tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with distributions on Calyxt&#146;s common stock. Copies of the information
returns reporting those distributions and withholding (if any) may also be made available to the tax authorities in the country in which you are a resident under the provisions of an applicable income tax treaty or agreement. Unless you comply with
certification procedures to establish that you are not a United States person, information returns may also be filed with the IRS in connection with the proceeds from a sale or other disposition of Calyxt&#146;s common stock to or through the U.S.
office (and, in certain cases, the foreign office) of a broker. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may be subject to backup withholding on payments on Calyxt&#146;s common stock or on the
proceeds from a sale or other disposition of Calyxt&#146;s common stock unless you comply with certification procedures to establish that you are not a United States person or otherwise establish an exemption. Compliance with the certification
procedures required to claim a reduced rate of withholding under a treaty (including properly certifying <FONT STYLE="white-space:nowrap">your&nbsp;non-U.S.&nbsp;status</FONT> on an IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,&nbsp;IRS</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E&nbsp;or</FONT></FONT> other appropriate version of IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8&nbsp;(or</FONT> appropriate successor form)) generally will satisfy the certification requirements necessary to avoid backup withholding as well. Notwithstanding the foregoing, U.S. federal backup
withholding may apply if the payor has actual knowledge, or reason to know, that you are a United States person. Amounts withheld under the backup withholding rules are not additional taxes and may be refunded or credited against your U.S. federal
income tax liability, provided the required information is timely furnished to the IRS. You are urged to consult your tax advisor regarding the application of backup withholding and the availability of and procedure for obtaining an exemption from
backup withholding in your particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code commonly referred to as &#147;FATCA&#148; require withholding of 30% on payments of dividends on Calyxt&#146;s common
stock, as well as payments of gross proceeds of dispositions of Calyxt&#146;s common stock, to a &#147;foreign financial institution&#148; (which is broadly defined for this purpose and in general includes investment vehicles) and certain other <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> entities unless various U.S. information reporting and due diligence requirements (generally relating to ownership by United States persons of interests in or accounts with those entities) have been
satisfied or an exemption applies. However, the IRS has issued proposed Treasury regulations that eliminate FATCA withholding on payments of gross proceeds (but not on payments of dividends). Pursuant to the preamble to the proposed Treasury
regulations, any applicable withholding agent may (but is not required to) rely on this proposed change to FATCA withholding until final Treasury regulations are issued or withdrawn. An intergovernmental agreement between the United States and an
applicable foreign country may modify these requirements. If FATCA withholding is imposed, a beneficial owner that is not a foreign financial institution generally may obtain a refund of any amounts withheld by filing a U.S. federal income tax
return (which may entail significant administrative burden). You should consult your tax advisor regarding the effects of FATCA on your investment in Calyxt&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will not pay any additional amounts <FONT STYLE="white-space:nowrap">to&nbsp;Non-U.S.</FONT> Holders with respect to any amounts
withheld, including pursuant to FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT
IS NOT TAX ADVICE. YOU SHOULD CONSULT YOUR TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.&nbsp;TAX</FONT> CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF CALXYT&#146;S COMMON
STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jones Day, New York, New York, will pass upon the validity of the securities offered hereby. Jefferies LLC is being represented in connection
with this offering by Latham&nbsp;&amp; Watkins LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Calyxt, Inc. appearing in Calyxt&#146;s Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the
year ended December&nbsp;31, 2021 have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements
are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst&nbsp;&amp; Young LLP pertaining to such financial statements to the extent covered by consents
filed with the SEC given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_13"></A>WHERE YOU
CAN FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has filed with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to the shares of common stock being offered hereby. This prospectus supplement and accompanying prospectus are part of the registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> Calyxt filed with the SEC under the Securities Act and do not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement to any of
Calyxt&#146;s contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference
into this prospectus supplement for a copy of such contract, agreement or other document. For further information about Calyxt and the common stock offered hereby, you are referred you to the registration statement and the exhibits filed with the
registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is subject to the information and reporting requirements of the Exchange Act and, in accordance with this
law, is required to file periodic reports, proxy statements and other information with the SEC. You can read Calyxt&#146;s SEC filings, including the registration statement, over the internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt makes available free of charge, on or through the investor relations section of our website, Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after it electronically files such material with, or furnishes it to, the SEC. The information found on Calyxt&#146;s website, www.calyxt.com, other than as
specifically incorporated by reference in this prospectus supplement, is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom385878_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows Calyxt to incorporate by reference much of the information the Company files with them. This allows Calyxt to disclose
important information to you by referring those publicly filed documents. The information that Calyxt incorporates by reference in this prospectus supplement is considered to be part of this prospectus supplement. Because Calyxt is incorporating by
reference future filings with the SEC, this prospectus supplement is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus supplement. This means that you must look
at all of the SEC filings that Calyxt incorporates by reference to determine if any of the statements in this prospectus supplement or in any document previously incorporated by reference have been modified or superseded. This prospectus supplement
incorporates by reference the documents listed below (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38161)</FONT> and any future filings the Company makes with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case,
other than those documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000095017022002808/clxt-20211231.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;
10-K</FONT></A> for the year ended December 31, 2021 (including the information in Part III incorporated therein by reference from Calyxt&#146;s Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312522109435/d549519ddef14a.htm">Schedule&nbsp;14A
</A>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522142416/d327324d10q.htm">March&nbsp;31,
 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522212583/d368508d10q.htm">June&nbsp;30, 2022</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather than
filed) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522046086/d197864d8k.htm">February&nbsp;
18, 2022</A> (solely with respect to Item 8.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522049605/d297063d8k.htm">February&nbsp;
23, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522086783/d340165d8k.htm">March&nbsp;
28, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522166294/d337451d8k.htm">June&nbsp;
2, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522248722/d378311d8k.htm">September&nbsp;22, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of Calyxt&#146;s common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312517231512/d433769d8a12b.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A> filed on July&nbsp;20, 2017, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt also incorporates by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus supplement is a part and prior to effectiveness of such registration statement, until Calyxt
files a post-effective amendment that indicates the termination of the offering of the shares of Calyxt&#146;s common stock made by this prospectus supplement and will become a part of this prospectus supplement from the date that such documents are
filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede any information in
any document Calyxt previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g385878g00m03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Subscription Rights </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. (&#147;Calyxt&#148; or the &#147;Company&#148;) may offer and sell from time to time in one or more offerings shares of its common
stock, par value $0.0001 per share (&#147;common stock&#148;), shares of preferred stock, warrants, subscription rights, units or debt securities for an aggregate offering price of $50,000,000. Any of these securities may be offered separately or in
combination at prices and on other terms to be determined at the time of the offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;16, 2022, the aggregate market
value of the Company&#146;s outstanding common equity held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or public float, was $5.9&nbsp;million, based on 22,593,988 shares of the Company&#146;s common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> and a per share price of $0.26, which equaled the closing price of the Company&#146;s common stock on the Nasdaq Global Market on such date. Pursuant to General Instruction I.B.6 of Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> in no event will the Company sell securities in a primary offering with a value exceeding more than <FONT STYLE="white-space:nowrap">one-third</FONT> of its public float in any
<FONT STYLE="white-space:nowrap">12-month</FONT> period so long as its public float remains below $75,000,000. If subsequent to the date of this prospectus the Company&#146;s public float equals or exceeds $75,000,000, such <FONT
STYLE="white-space:nowrap">one-third</FONT> limitation on sales shall not apply to sales subsequently made pursuant to this prospectus. During the 12 calendar months prior to and including the date of this prospectus supplement, we have offered and
sold $388.00 worth of our securities pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time
the Company offers any securities pursuant to this prospectus, it will provide a prospectus supplement that will provide the specific terms of the securities to the extent those terms are not described in this prospectus or are different from the
terms described in this prospectus. The prospectus supplements may also add to, update or change information contained in this prospectus. In addition, the Company may supplement, update or change any of the information contained in this prospectus
by incorporating information by reference into this prospectus. You should read this prospectus, any applicable prospectus supplements and any documents incorporated by reference carefully before you invest. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may offer these securities directly to investors, through agents, underwriters or dealers, or through a combination of these
methods. Each applicable prospectus supplement will provide the terms of the plan of distribution relating to the specific offering. If any agents, dealers or underwriters are involved in the sale of any securities, the applicable prospectus
supplement will set forth their names and any applicable commissions or discounts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s common stock is listed on the Nasdaq
Global Market (&#147;Nasdaq&#148;) under the symbol &#147;CLXT.&#148; On September&nbsp;16, 2022, the closing sale price of the common stock on Nasdaq was $0.26 per share. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in Calyxt&#146;s securities involves risks. See &#147;<A HREF="#toc385878_4">Risk Factors</A>&#148; on page&nbsp;4 and any risk
factors included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before investing in Calyxt&#146;s securities. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is September&nbsp;26, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_7">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_8">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_10">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_14">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc385878_15">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that Calyxt filed with the Securities
and Exchange Commission (the &#147;SEC&#148;) utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, Calyxt may offer and sell from time to time any combination of the securities described in this prospectus in
one or more offerings in amounts, at prices and on terms that Calyxt will determine at the time of the offering. This prospectus and the documents incorporated by reference into this prospectus provide you with a general description of the
securities that may be sold under this shelf registration statement. In connection with a specific offering, Calyxt may provide a prospectus supplement and may also provide you with a free writing prospectus that will contain specific information
about the terms of that offering. The prospectus supplement or free writing prospectus, if any, may also add to, update or change information contained in this prospectus. Before purchasing any securities, you should carefully read both this
prospectus, any applicable accompanying prospectus supplement and any free writing prospectus prepared by or on behalf of Calyxt, together with the additional information described under the heading &#147;Where You Can Find Additional
Information&#148; in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Calyxt has not authorized any other person to provide you with any information different than
that contained or incorporated by reference in this prospectus and any applicable accompanying prospectus supplement or free writing prospectus. If anyone provides you with different or inconsistent information, you should not rely on it as having
been authorized by Calyxt. Calyxt is not making offers to sell the securities and is not soliciting offers to buy the securities in any jurisdiction where an offer or solicitation is not permitted. The information in this prospectus is accurate only
as of the date on the front cover. You should not assume that the information contained in this prospectus, including any information incorporated in this prospectus by reference, any applicable accompanying prospectus supplement or any free writing
prospectus prepared by Calyxt, is accurate as of any date other than the date on the front of these documents. Calyxt&#146;s business, financial condition, results of operations and prospects may have changed since such date. Neither the delivery of
this prospectus nor any sale made under it implies that there has been no change in Calyxt&#146;s affairs or that the information in this prospectus is correct as of any date after the date of this prospectus. You are encouraged to consult your own
counsel, accountant and other advisors for legal, tax, business, financial and related advice regarding an investment in Calyxt&#146;s securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout this prospectus, unless the context otherwise requires, the terms &#147;Calyxt,&#148; the &#147;Company&#148; and &#147;it&#148;
refer to Calyxt, Inc. The term &#147;Cellectis&#148; refers to Cellectis S.A., Calyxt&#146;s majority stockholder as of the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt owns the names PlantSpring and BioFactory. Calyxt also owns the trademarks
Calyxt<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Calyno<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and owns or licenses other trademarks, trade names, and service marks appearing in this this prospectus and any
prospectus supplement or free writing prospectus. The names and trademarks Cellectis<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and TALEN<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, along with any other trademarks,
trade names, and service marks of Cellectis appearing in this this prospectus and any prospectus supplement or free writing prospectus are the property of Cellectis. This prospectus, any prospectus supplement and any free writing prospectus may also
contain additional trade names, trademarks and service marks belonging to other companies. Calyxt does not intend its use or display of other parties&#146; trademarks, trade names, or service marks to imply, and such use or display should not be
construed to imply a relationship with, or endorsement or sponsorship of these other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is a plant-based
synthetic biology company that leverages its proprietary PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology platform to engineer plant metabolism to produce innovative, high-value plant-based chemistries for use in
customers&#146; materials and products. As plant-based solutions, the Company&#146;s synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. The Company is focused on developing these
synthetic biology solutions for customers in large and differentiated end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries, which are the Company&#146;s initial target markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Cellectis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is
currently a majority-owned subsidiary of Cellectis S.A. As of June&nbsp;30, 2022, Cellectis owned 51.3&nbsp;percent of Calyxt&#146;s 46,815,694 outstanding shares of common stock. Cellectis has certain contractual rights as well as rights pursuant
to Calyxt&#146;s certificate of incorporation and bylaws, in each case, for so long as it maintains threshold beneficial ownership levels in Calyxt&#146;s shares. Several of Cellectis&#146; rights remain in effect for so long as Cellectis
beneficially owns at least 15&nbsp;percent of Calyxt&#146;s outstanding shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt holds an exclusive license from Cellectis that
broadly covers the use of engineered nucleases for plant gene editing. This intellectual property covers methods to edit plant genes using &#147;chimeric restriction endonucleases,&#148; which include TALEN<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, CRISPR/Cas9, zinc finger nucleases, and some types of meganucleases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt was incorporated in the State of Delaware in 2010. The Company&#146;s corporate headquarters is located at 2800 Mount Ridge
Road, Roseville, Minnesota 55113 and Calyxt&#146;s phone number is (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> Calyxt&#146;s filings with the SEC are posted on its corporate website at www.calyxt.com. The information contained in, or
accessible through, Calyxt&#146;s corporate website does not constitute part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s common stock is listed on
the Nasdaq Global Market under the symbol &#147;CLXT.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated herein contain &#147;forward-looking statements&#148; within the meaning of the federal
securities laws, including Section&nbsp;27A of the Securities Act of 1933 (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has made these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. In some cases, you can identify these statements by forward-looking words such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;continue,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148;
&#147;might,&#148; &#147;plans,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;targets,&#148; &#147;will,&#148; or the negative of these terms and other similar terminology. Forward-looking statements in this prospectus
and the documents incorporated herein include statements about the Company&#146;s future financial performance, including its cash runway; its product pipeline and development; the Company&#146;s business model and strategies for the development,
commercialization and sales of commercial products; commercial demand for its synthetic biology solutions; the development and deployment of its PlantSpring technology platform; its ability to deploy and leverage its artificial intelligence and
machine learning (AIML) capabilities; the ability to scale production capability for its BioFactory production system; potential development agreements, partnerships, customer relationships, and licensing arrangements and their contribution to the
Company&#146;s financial results, cash usage, and growth strategies; the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s business and operating results; and anticipated trends in its business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other forward-looking statements are predictions and projections about future events and trends based on Calyxt&#146;s current
expectations, objectives, and intentions and are premised on current assumptions. Calyxt&#146;s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by
forward-looking statements due to a variety of factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of increased competition, including competition from a broader array of synthetic biology companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition for customers, partners, and licensees and the successful execution of development and licensing
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at its key facilities, including disruptions impacting its BioFactory production system;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">flaws in AIML algorithms, insufficiency of data inputs required by such algorithms, and human error in
interacting with AIML; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in customer preferences and market acceptance of its products; changes in market consensus as to what
attributes are required for a product to be considered &#147;sustainable&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of adverse events during development, including unsuccessful pilot production of plant-based
chemistries or field trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of improper handling of its product candidates during development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failures by third-party contractors; inaccurate demand forecasting or milestone and royalty payment projections;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of commercialization efforts by commercial partners or licensees; disruptions to supply chains,
including raw material inputs for its BioFactory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of changes or increases in oversight and regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or challenges regarding intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proliferation and continuous evolution of new technologies; management changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dislocations in the capital markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity and duration of the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the
resulting impact on macro-economic conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other important factors discussed under the heading &#147;Risk Factors&#148; in this prospectus, as may be
amended or supplemented by Calyxt&#146;s subsequent reports on Forms <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all
potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Any of these factors, in whole or in part, could materially and adversely affect Calyxt&#146;s
business, financial condition, results of operations and the price of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statement made by
Calyxt in this prospectus, any prospectus supplement and the documents incorporated by reference herein or therein is based only on information currently available to Calyxt and speaks only as of the date of this prospectus or such prospectus
supplement or incorporated document, as the case may be. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements after the date of the document in which such statement appears, whether as a
result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus together with the documents Calyxt has filed with the SEC that are incorporated by reference and any
prospectus supplement or free writing prospectus that the Company may authorize for use in connection with this offering completely and with the understanding that Calyxt&#146;s actual future results may be materially different from what Calyxt
currently expects. Calyxt qualifies all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in Calyxt&#146;s securities involves risk. You should carefully consider the risks and uncertainties described in this prospectus,
any prospectus supplement and the documents incorporated by reference herein or therein, including the risks and uncertainties described in Calyxt&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2021, as updated by the Company&#146;s subsequent filings under the Exchange Act that are incorporated by reference herein or in the applicable prospectus supplement. If any of these risks actually occur, Calyxt&#146;s business,
operating results, prospects or financial condition could be harmed. The risks below and incorporated by reference in this prospectus are not the only ones Calyxt faces. Additional risks not currently known to Calyxt or that Calyxt currently deems
immaterial may also affect Calyxt&#146;s business operations. For more information, see &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in a prospectus supplement prepared in connection with an offering of securities pursuant to this prospectus, the
net proceeds from the sale of any securities described in this prospectus will be used for general corporate purposes. General corporate purposes may include financing research and development; scaling production capacity; funding personnel and
infrastructure enhancements; repayment, repurchase or redemption of debt; repurchases of other securities; acquisitions; additions to working capital; capital expenditures and investments. Accordingly, Calyxt will have significant discretion over
the use of any net proceeds. Calyxt may provide additional or updated information on the use of net proceeds from the sale of the offered securities in an applicable prospectus supplement relating to the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a description of the material terms and provisions of Calyxt&#146;s amended and restated certificate of incorporation (the
&#147;Certificate of Incorporation&#148;) and Calyxt&#146;s amended and restated bylaws <FONT STYLE="white-space:nowrap">(&#147;By-laws&#148;)</FONT> as well as relevant terms and provisions of Calyxt&#146;s indemnification agreements for directors
and officers and Delaware law affecting the rights of Calyxt&#146;s stockholders. This summary does not purport to be complete and is qualified in its entirety by the provisions of Calyxt&#146;s Certificate of Incorporation, <FONT
STYLE="white-space:nowrap">By-laws</FONT> and such indemnification agreements. Copies of Calyxt&#146;s Certificate of Incorporation, <FONT STYLE="white-space:nowrap">By-laws</FONT> and indemnification agreements have been filed with the SEC and are
incorporated by reference into the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s authorized capital stock consists of 275,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of
preferred stock, par value $0.0001 per share. The only equity securities currently outstanding are shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2022, there were 46,815,694 shares of common stock issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> The holders of Calyxt&#146;s common stock are entitled to one vote per share on all matters to be voted upon by the
stockholders. Holders of Calyxt&#146;s common stock do not have cumulative voting rights in the election of directors. Accordingly, the holders of a majority of the voting power of Calyxt&#146;s common stock could, if they so choose, elect all the
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights.</I> Holders of common stock are entitled to receive dividends if, as and when declared by Calyxt&#146;s
Board of Directors, out of Calyxt&#146;s legally available assets, in cash, property or shares of Calyxt&#146;s capital stock, after payments of dividends required to be paid on outstanding preferred stock, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Distributions in Connection with Mergers or Other Business Combinations.</I> Upon a merger, consolidation or substantially similar
transaction, holders of common stock will be entitled to receive equal per share payments or distributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights.</I>
Upon Calyxt&#146;s liquidation, dissolution or winding up, any business combination or a sale or disposition of all or substantially all of Calyxt&#146;s assets, the assets legally available for distribution to Calyxt&#146;s stockholders will be
distributable ratably among the holders of the common stock, subject to prior satisfaction of all outstanding debts and other liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholders Agreement.</I> In connection with Calyxt&#146;s IPO, Calyxt entered into a stockholders agreement dated July&nbsp;25,
2017 with Cellectis (as amended from time to time, the &#147;Stockholders Agreement&#148;), pursuant to which Cellectis has certain specified rights. Pursuant to the Stockholders Agreement, for so long as Cellectis beneficially owns at least 50% of
the then-outstanding shares of Calyxt&#146;s shares of Common Stock, Cellectis has certain rights, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any modification to Calyxt&#146;s or any future subsidiary&#146;s share capital (e.g., share capital
increase or decrease), the creation of any subsidiary, any grant of stock-based compensation, any distributions or initial public offering, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> liquidation, winding up or <FONT
STYLE="white-space:nowrap">carve-out</FONT> transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve Calyxt&#146;s annual business plan and annual budget and any modification thereto;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any external growth transactions exceeding $500,000 and not included in the approved annual business
plan and annual budget; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any investment and disposition decisions exceeding $500,000 and not included in the approved annual
business plan and annual budget (excluding the purchase and sale of inventory as a part of the normal course of business); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any related-party agreement and any agreement or transaction between the executives or stockholders of
Calyxt, on the one hand, and Calyxt or any of its subsidiaries, on the other hand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any decision pertaining to the recruitment, dismissal/removal, or increase of the compensation of
executives and corporate officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any material decision relating to a material litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any decision relating to the opening of a social or restructuring plan or <FONT
STYLE="white-space:nowrap">pre-insolvency</FONT> proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any buyback by Calyxt of its own shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any new borrowings or debts exceeding $500,000 and early repayment of loans, if any (it being
understood that Cellectis will approve the entering into of contracts for revolving loans and other short-term loans and the repayment of such for financing general operating activities, such as revolving loans for inventory or factoring of
receivables); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve grants of any pledges on securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to develop new activities and businesses not described in the annual business plan and annual budget;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve entry into any material agreement or partnership; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any offshore and relocation activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cellectis has the following rights for so long as it beneficially owns at least 15% of the then outstanding shares of
Calyxt&#146;s common stock, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to nominate the greater of three members of Calyxt&#146;s Board of Directors or a majority of the directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to designate the Chairman of Calyxt&#146;s Board of Directors and one member to each of the audit committee of
the Board of Directors, the compensation committee of the Board of Directors and the nominating and corporation governance committee of the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any amendments to Calyxt&#146;s Certificate of Incorporation or
<FONT STYLE="white-space:nowrap">By-laws</FONT> that would change the name of the company, its jurisdiction of incorporation, the location of its principal executive offices, the purpose or purposes for which Calyxt is incorporated or the Cellectis
approval items set forth in the stockholders agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the payment of any regular or special dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the commencement of any proceeding for the voluntary dissolution, winding up or bankruptcy of Calyxt
or a material subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any public or private offering, merger, amalgamation or consolidation of us or the spinoff of a
business of Calyxt&#146;s or any sale, conveyance, transfer or other disposition of Calyxt&#146;s assets; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any change to Calyxt&#146;s Board of Directors contrary to the stockholders agreement or the
Company&#146;s Certificate of Incorporation or <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Matters.</I>
Calyxt&#146;s Certificate of Incorporation does not entitle holders of Calyxt&#146;s common stock to preemptive rights. No redemption or sinking fund provisions apply to Calyxt&#146;s common stock. The rights, preferences and privileges of holders
of Calyxt&#146;s common stock are subject to, and may be adversely affected by, the rights of holders of any series of preferred stock that Calyxt may designate in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Certificate of Incorporation authorizes its Board of Directors, without further action by the stockholders (unless so required by
applicable law or Nasdaq listing standards), to issue preferred stock in one or more series, to increase or decrease the number of shares of any series subsequent to the issuance of that series, but not below the number of shares of such series then
outstanding, and to determine the preferences, limitations and rights of any shares of preferred stock that Calyxt chooses to issue, without vote or action by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will fix the designations, powers, preferences and relative, participating, optional or other rights, if any, of the preferred stock of
each such series, as well as any qualifications, limitations or restrictions thereon, in the certificate of designation relating to that series. Calyxt will file as an exhibit to the registration statement of which this prospectus is a part, or will
incorporate by reference from reports that Calyxt files with the SEC, the form of any certificate of designation that sets forth the terms of the series of preferred stock Calyxt is offering before the issuance of that series of preferred stock. If
Calyxt offers preferred stock, the terms of the particular series of preferred stock will be described in the applicable prospectus supplement. This description will include (to the extent applicable): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the applicable series number of shares of such series Calyxt is offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, period and payment date and method of calculation for dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on Calyxt&#146;s ability to
exercise those redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into Calyxt&#146;s common stock or any other security of the
Company, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable for Calyxt&#146;s common stock or any other security of the
Company, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material United States federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if Calyxt
liquidates, dissolves or winds up its affairs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with
the series of preferred stock as to dividend rights and rights if Calyxt liquidates, dissolves or winds up its affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law (the &#147;DGCL&#148;) provides that the holders of preferred stock will have the
right to vote separately as a class (or, in some cases, as a series) on an amendment to Calyxt&#146;s Certificate of Incorporation if the amendment would change the par value, the number of authorized shares of the class or the powers, preferences
or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Board of Directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of Calyxt&#146;s common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the
effect of delaying, deferring or preventing a change in control of Calyxt and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. Additionally, the issuance of preferred stock may
have the effect of decreasing the market price of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Anti-Takeover Law and Provisions of Calyxt&#146;s Charter and
Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provisions may make a change in control of Calyxt&#146;s business more difficult and could delay, defer or
prevent a tender offer or other takeover attempt that a stockholder might consider to be in its best interest, including takeover attempts that might result in the payment of a premium to stockholders over the market price for their shares. These
provisions also may promote the continuity of Calyxt&#146;s management by making it more difficult for a person to remove or change the incumbent members of Calyxt&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized but Unissued Shares; Undesignated Preferred Stock.</I> The authorized but unissued shares of Calyxt&#146;s common stock will be
available for future issuance without stockholder approval. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions and employee benefit plans. In addition,
Calyxt&#146;s Board of Directors may authorize, without stockholder approval, the issuance of undesignated preferred stock with voting rights or other rights or preferences designated from time to time by Calyxt&#146;s Board of Directors. The
existence of authorized but unissued shares of common stock or preferred stock may enable Calyxt&#146;s Board of Directors to render more difficult or to discourage an attempt to obtain control of Calyxt by means of a merger, tender offer, proxy
contest or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Election and Removal of Directors.</I> Calyxt&#146;s Board of Directors consists of not less than five nor more
than eleven directors, excluding any directors elected by holders of preferred stock pursuant to provisions of any applicable series of preferred stock entitling the holders thereof to separately elect directors. The exact number of directors will
be fixed from time to time by resolution of Calyxt&#146;s Board of Directors. As of the date of this prospectus, Calyxt&#146;s Board of Directors has eight members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholders Agreement, Cellectis has the right to nominate the greater of three directors or a majority of directors to
Calyxt&#146;s Board of Directors so long as it continues to own at least 15% of the then-outstanding shares of Calyxt&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after Cellectis beneficially owns less than 50% of Calyxt&#146;s then outstanding common stock, Calyxt&#146;s Certificate of
Incorporation provides that directors may be removed only for cause and only by the affirmative vote of holders of a majority of Calyxt&#146;s then outstanding stock. Prior to such time, directors may be removed with or without cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Classified Board of Directors.</I> Calyxt&#146;s Board of Directors currently is not
classified. However, Calyxt&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> provide that Calyxt&#146;s Board of Directors will be classified with approximately <FONT STYLE="white-space:nowrap">one-third</FONT>
of the directors elected each year at such time as Cellectis no longer holds at least 50% of Calyxt&#146;s then outstanding common stock. The number of directors will be fixed from time to time by a majority of the total number of directors that
Calyxt would have at the time such number is fixed if there were no vacancies. The directors will be divided into three classes, designated class I, class II and class III. Each class will consist, as nearly as may be possible, of <FONT
STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting the entire Board of Directors. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be
elected for a three-year term and until their successors are duly elected and qualified. In addition, if the number of directors is changed, any increase or decrease will be apportioned by Calyxt&#146;s Board of Directors among the classes so as to
maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class or from the removal from office, death, disability, resignation
or disqualification of a director or other cause will hold office for a term that will coincide with the remaining term of that class, but in no case will a decrease in the number of directors have the effect of removing or shortening the term of
any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Director Vacancies.</I> Calyxt&#146;s Certificate of Incorporation authorizes only its Board of Directors to
fill vacant directorships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>No Cumulative Voting.</I> Calyxt&#146;s Certificate of Incorporation provides that stockholders do not have
the right to cumulate votes in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Special Meetings of Stockholders</I>. At any time after Cellectis
beneficially owns less than 50% of Calyxt&#146;s then outstanding common stock, Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> and Certificate of Incorporation provide that special meetings of its stockholders may only be called by
the Board of Directors. Prior to such time, a special meeting may also be called by the secretary of the Company at the request of stockholders holding a majority of the outstanding shares entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance Notice Procedures for Director Nominations.</I> Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> establish advance
notice procedures for stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders. Although Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> do not give the Board of Directors
the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the <FONT STYLE="white-space:nowrap">By-laws</FONT> may have the effect of precluding the conduct of certain business at a meeting if the
proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Action by Written Consent.</I> At any time after Cellectis beneficially owns less than 50% of Calyxt&#146;s then outstanding common stock,
Calyxt&#146;s <FONT STYLE="white-space:nowrap">By-laws</FONT> and Certificate of Incorporation provide that any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders
and may not be effected by any consent in writing in lieu of a meeting of such stockholders, subject to the rights of the holders of any series of preferred stock. Prior to such time, such actions may be taken without a meeting by written consent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amending Calyxt&#146;s Certificate of Incorporation and Bylaws.</I> At any time after Cellectis beneficially owns less than 50% of
Calyxt&#146;s then outstanding common stock, Calyxt&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended by the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of Calyxt&#146;s common stock. Prior to such time, Calyxt&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended by the affirmative vote of the
holders of a majority of the voting power of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusive Jurisdiction.</I> Calyxt&#146;s Certificate of
Incorporation provides that, unless it consents to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on Calyxt&#146;s behalf,
any action asserting a claim of breach of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fiduciary duty owed by any of the Company&#146;s directors, officers, or other employees to Calyxt or to its stockholders, any action asserting a claim arising pursuant to the DGCL, or any action
asserting a claim governed by the internal affairs doctrine. Notwithstanding the foregoing, because the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce duties or liabilities created by the Exchange Act or the
rules and regulations thereunder, the exclusive forum provision does not apply to any action arising under the Exchange Act. Although the exclusive forum provision applies, to the extent permitted by law, to Securities Act claims, the Securities Act
creates concurrent federal and state jurisdiction over suits brought to enforce duties or liabilities created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce this
exclusive forum provision with respect to a Securities Act claim. Neither Calyxt nor its stockholders may waive compliance with the federal securities laws or the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Business Combinations with Interested Stockholders.</I> Subject to certain exceptions, Section&nbsp;203 of the DGCL prohibits a public
Delaware corporation from engaging in a business combination (as defined in such section) with an &#147;interested stockholder&#148; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such
corporation or any person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (i)&nbsp;prior to such time the Board of Directors of such corporation approved
either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii)&nbsp;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock
owned by the interested stockholder) those shares owned (A)&nbsp;by persons who are directors and also officers of such corporation and (B)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii)&nbsp;at or subsequent to such time the business combination is approved by the Board of Directors of such corporation and authorized at a meeting of
stockholders (and not by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or
an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. Calyxt has expressly elected not to be governed by the &#147;business
combination&#148; provisions of Section&nbsp;203 of the DGCL until after such time as Cellectis no longer beneficially owns at least 50% of Calyxt&#146;s common stock. At that time, such election shall be automatically withdrawn and Calyxt will
thereafter be governed by the &#147;business combination&#148; provisions of Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the
corporation or its officers, directors or stockholders. Calyxt&#146;s Certificate of Incorporation renounces, to the maximum extent permitted from time to time by Delaware law, any interest or expectancy that Calyxt has in, or right to be offered an
opportunity to participate in, specified business opportunities that are from time to time presented to Calyxt&#146;s officers, directors or stockholders or their respective affiliates, other than those officers, directors, stockholders or
affiliates who are Calyxt&#146;s or its subsidiaries&#146; employees. Calyxt&#146;s Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Cellectis or any of its affiliates or any director who is not employed by
Calyxt, or his or her affiliates has any duty to refrain from (i)&nbsp;engaging in a corporate opportunity in the same or similar lines of business in which Calyxt or its subsidiaries now engage or propose to engage or (ii)&nbsp;otherwise competing
with Calyxt or its subsidiaries. In addition, to the fullest extent permitted by law, in the event that Cellectis or any <FONT STYLE="white-space:nowrap">non-employee</FONT> director acquires knowledge of a potential transaction or other business
opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for Calyxt or its affiliates, such person has no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duty to communicate or offer such transaction or business opportunity to Calyxt or any of its affiliates and they may take any such opportunity for themselves or offer it to another person or
entity. Calyxt&#146;s Certificate of Incorporation does not renounce its interest in any business opportunity that is expressly offered to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director solely in his or her capacity as a director of
Calyxt. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for Calyxt unless Calyxt would be permitted to undertake the opportunity under its Certificate of Incorporation, Calyxt
has sufficient financial resources to undertake the opportunity and the opportunity would be in line with Calyxt&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholders Agreement provides Cellectis with certain registration rights, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration</I>&#151;Cellectis may request that Calyxt register for resale all or a portion of their shares. Any such request must
cover a quantity of shares with an anticipated aggregate offering price of at least $25.0&nbsp;million. To the extent Calyxt is a well-known seasoned issuer, Cellectis may also request that Calyxt file an automatic shelf registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> that covers the registrable securities requested to be registered. Depending on certain conditions, Calyxt may defer a demand registration for up to 90 days in any twelve month period. Cellectis will
agree pursuant to a contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> not to exercise any of its rights under the registration rights agreement during a <FONT STYLE="white-space:nowrap">90-day</FONT> restricted period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights</I>&#151;In the event that Calyxt proposes to register any of its securities under the Securities Act of
1933, either for its own account or for the account of its other security holders, Cellectis is entitled to certain piggyback registration rights allowing it to include its shares in the registration, subject to certain marketing and other
limitations. As a result, whenever Calyxt proposes to file a registration statement under the Securities Act, Cellectis is entitled to notice of the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expenses; Indemnification</I>&#151;The registration rights provides that Calyxt must pay all registration expenses (other than the
underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The registration rights contain customary indemnification and contribution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term</I>&#151;The registration rights will remain in effect with respect to any shares covered by the Stockholders Agreement until
(i)&nbsp;all of Cellectis&#146; shares have been sold pursuant to an effective registration statement under the Securities Act; (ii)&nbsp;all of Cellectis&#146; shares have been sold to the public pursuant to Rule 144 under the Securities Act; or
(iii)&nbsp;Cellectis owns less than 10% of the then outstanding shares of Calyxt&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification and Limitations on
Directors&#146; Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL grants each Delaware corporation the power to indemnify any person who is or
was a director, officer, employee or agent of a corporation, against expenses, including attorneys&#146; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of serving or having served in any such capacity, if he or she acted in good
faith in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A Delaware
corporation may similarly indemnify any such person in actions by or in the right of the corporation if he or she acted in good faith in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no
indemnification may be made in respect of any claim, issue or matter as to which the person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the court in which the action
was brought determines that, despite adjudication of liability, but in view of all of the circumstances of the case, the person is fairly and reasonably entitled to indemnity for expenses which the Delaware Court of Chancery or other court shall
deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL enables a corporation in its certificate of
incorporation, or an amendment thereto, to eliminate or limit the personal liability of a director to the corporation or its stockholders for monetary damages for violations of the director&#146;s fiduciary duty as a director, except (i)&nbsp;for
any breach of the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;pursuant to
Section&nbsp;174 of the DGCL (providing for director liability with respect to unlawful payment of dividends or unlawful stock purchases or redemptions) or (iv)&nbsp;for any transaction from which a director derived an improper personal benefit.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Certificate of Incorporation indemnifies its directors and principal officers to the fullest extent permitted by Delaware
law and Calyxt&#146;s Certificate of Incorporation also allows Calyxt&#146;s Board of Directors to indemnify other employees. This indemnification extends to the payment of judgments in actions against officers and directors and to reimbursement of
amounts paid in settlement of such claims or actions and may apply to judgments in favor of the corporation or amounts paid in settlement to the corporation. This indemnification also extends to the payment of attorneys&#146; fees and expenses of
principal officers and directors in suits against them where the officer or director acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, Calyxt&#146;s best interests, and, with respect to any criminal
action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. This right of indemnification is not exclusive of any right to which the officer or director may be entitled as a matter of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s directors and officers are insured pursuant to a &#147;directors and officers&#148; insurance policy, which provides protection
against <FONT STYLE="white-space:nowrap">un-indemnified</FONT> losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for losses incurred by Calyxt in response to securities claims involving
directors and officers. The policy contains various customary exclusions for policies of this type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Calyxt&#146;s Board of
Directors has adopted a policy to enter into an indemnification agreement with each of its directors and officers, which provide for certain advancement and indemnification rights. Each indemnification agreement provides, subject to certain
exceptions, to indemnify and hold harmless the director or officer to the fullest extent permitted by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any
indemnification available to directors affiliated with Cellectis, Calyxt has agreed (i)&nbsp;that it is the indemnitor of first resort with respect to any amounts incurred or sustained in connection with such person&#146;s role as a director of
Calyxt, (ii)&nbsp;that it will be responsible for, and required to advance, the full amount of such amounts without regard to any rights such person may have, or be pursuing, against Cellectis, and (iii)&nbsp;to irrevocably waive, relinquishe and
release Cellectis from any and all claims for contribution, subrogation or any other recovery in respect of such amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt believes
that the limitation of liability and indemnification provisions in its Certificate of Incorporation, <FONT STYLE="white-space:nowrap">By-laws,</FONT> indemnification agreements and insurance policies are necessary to attract and retain qualified
directors and officers. However, these provisions may discourage derivative litigation against directors and officers, even though an action, if successful, might benefit Calyxt and its stockholders. Furthermore, a stockholder&#146;s investment may
be adversely affected to the extent Calyxt pays the costs of settlement and damage awards against directors and officers as required or allowed by these limitations of liability and indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of Calyxt&#146;s directors, officers, employees or agents as to which
indemnification is sought from Calyxt, nor is the Company aware of any threatened litigation or proceeding that may result in an indemnification claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s shares of common stock are listed on the Nasdaq Global Market under the symbol &#147;CLXT.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for Calyxt&#146;s common stock is Broadridge Corporate Issuer Solutions, Inc., 1155 Long Island Avenue, Edgewood, NY 11717. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_7"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt may issue warrants to purchase common stock, preferred stock, debt securities or any combination thereof. Each warrant will entitle the
holder to purchase for cash the amount of common stock, preferred stock, debt securities or units at the exercise price stated or determinable in a prospectus supplement for the warrants. Warrants may be issued independently or together with any
other securities and may be attached to, or separate from, such securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between Calyxt and a warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, holders of warrants will not be entitled to any rights with respect to the
securities for which warrants are exercisable prior to the issuance of securities. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus
supplement. These terms will include some or all of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the warrants will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, amount and terms of the securities for which the warrants are exercisable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the other securities, if any, with which the warrants are to be issued and the
number of warrants issued with each other security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or
the exercise price of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the securities purchasable upon exercise of the warrants will be separately
transferable, if applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence, and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maximum or minimum number of warrants that may be exercised at any time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and
exercise of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description in the applicable prospectus supplement of any warrants Calyxt offers will
not necessarily be complete and will be qualified in its entirety by reference to the applicable warrant or warrant agreement, which will be filed with the SEC if Calyxt offers warrants. You are urged to read the applicable warrant or warrant
agreement, as applicable, and any applicable prospectus supplement in their entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_8"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt may issue subscription rights to purchase common stock, preferred stock, debt securities or any combination thereof. These subscription
rights may be offered independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection with any offering of subscription rights,
Calyxt may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any subscription rights Calyxt offers, if any, will, to the extent applicable, include specific terms
relating to the offering, including some or all of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price, if any, for the subscription rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price payable for Calyxt&#146;s common stock, preferred stock or debt securities upon the exercise
of the subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subscription rights to be issued to each stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares and terms of the common stock, preferred stock or debt securities which may be purchased per
each subscription right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights are transferable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the subscription rights, including the terms, procedures and limitations relating to the
exchange and exercise of the subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the subscription rights shall commence, and the date on which the
subscription rights shall expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights may include an over-subscription privilege with respect to
unsubscribed securities or an over-allotment privilege to the extent the securities are fully subscribed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the material terms of any standby underwriting or purchase arrangement into which Calyxt may enter
in connection with the offering of subscription rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description in the applicable prospectus supplement of any
subscription rights Calyxt offers will not necessarily be complete and will be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC if Calyxt offers subscription rights. You are
urged to read the applicable subscription rights certificate and any applicable prospectus supplement in their entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt may issue units comprising one or more securities described in this prospectus in any combination (but not securities of third parties)
as specified in a related prospectus supplement or a free writing prospectus. Units may be issued pursuant to the terms of a unit agreement, which may provide that the securities included in the unit may not be held or transferred separately at any
time or at any time before a specified date. A copy of the forms of any unit agreement or unit certificate, as applicable, relating to any particular issue of units will, if applicable, be filed with the SEC when Calyxt issues units, and you should
read those documents for provisions that may be important to you. For more information on how you can obtain copies of the forms of the unit agreement and the related unit certificate, see &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_10"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms summarized below will apply generally to any debt securities that Calyxt may offer under this prospectus, the particular terms of any debt securities that Calyxt may offer will be described in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, references to the indenture also refer to any supplemental
indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will issue the debt securities under the indenture
that it will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended (the &#147;Trust Indenture Act&#148;). Calyxt has filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that Calyxt files with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. You are urged to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that Calyxt may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that Calyxt may issue. It provides that Calyxt may issue debt securities up to the principal amount that Calyxt may authorize and may be in any currency or currency unit that Calyxt may designate. Except for the limitations
on consolidation, merger and sale of all or substantially all of Calyxt&#146;s assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection
against changes in Calyxt&#146;s operations, financial condition or transactions involving Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt may issue the debt securities
issued under the indenture as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued
with &#147;original issue discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt
securities issued with OID will be described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement
will describe the terms of the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into or exchangeable for another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt&#146;s right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, Calyxt may, at Calyxt&#146;s option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which Calyxt is obligated, pursuant to any
mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which Calyxt will issue the series of debt securities, if other than denominations of $1,000
and any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for Calyxt&#146;s obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at Calyxt&#146;s
option or the holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at Calyxt&#146;s or the holders&#146;
option and the terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which Calyxt will pay amounts in addition to the stated interest, premium,
if any, and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by Calyxt or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
applicable prospectus supplement will set forth the terms on which a series of debt securities may be convertible into or exchangeable for Calyxt&#146;s common stock or its other securities. The applicable prospectus supplement will include
provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at Calyxt&#146;s option. The applicable prospectus supplement may include provisions pursuant to which the number
of shares of Calyxt&#146;s common stock or Calyxt&#146;s other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise provided in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts Calyxt&#146;s ability to merge or consolidate, or sell, convey, transfer or otherwise
dispose of its assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of Calyxt&#146;s) must assume all of Calyxt&#146;s obligations under the indenture or the debt
securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indenture with respect to any series of debt securities that Calyxt may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Calyxt fails to pay any installment of interest on such series of debt securities, as and when the same shall
become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by Calyxt in accordance with the terms of any indenture supplemental thereto shall not constitute a
default in the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Calyxt fails to pay the principal of, or premium, if any, on such series of debt securities as and when the
same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of
the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Calyxt fails to observe or perform any other covenant or agreement contained in the debt securities of such
series or the indenture, other than a covenant specifically relating to another series of debt securities, and such failure continues for 90 days after Calyxt receives written notice of such failure, requiring the same to be remedied and stating
that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is
continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to Calyxt in writing, and to
the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, of such series of debt securities due and payable immediately. If an event of default specified in the last bullet
point above occurs with respect to Calyxt, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences (including acceleration described in the preceding paragraph), except that such waivers of defaults or events of default regarding payment of principal, premium, if any, or interest, require
that Calyxt shall have paid or set aside with the Trustee sufficient funds to pay all amounts then due and payable otherwise then due and payable otherwise then by acceleration. Any waiver shall cure the default or event of default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no
obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred
on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request for the Trustee to initiate such action or proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions, within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if Calyxt defaults in the payment of the principal,
premium, if any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On an annual basis, Calyxt will provide statements to the Trustee regarding its
compliance with specified covenants in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the prospectus supplement applicable to a particular series of debt securities, Calyxt and the trustee may change
an indenture without the consent of any holders with respect to specific matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation,
Merger or Sale&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants, restrictions, conditions for the benefit of the holders of all or any series of debt
securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon Calyxt in the
indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
Calyxt and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless otherwise provided in the prospectus supplement
applicable to a particular series of debt securities, Calyxt and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that Calyxt can elect to be discharged from its obligations with respect to one or more series of debt securities that
shall become due and payable within one year or are to be called for redemption within one year, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise its rights to be discharged, Calyxt must irrevocably deposit with the trustee money or government obligations sufficient
to pay all the principal of, any premium, if any, and interest on, the debt securities of the series when payments are due on the date of maturity or the date fixed for redemption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will
issue the debt securities of each series only in fully registered form without coupons and, unless otherwise provided in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple in excess thereof. The indenture
provides that Calyxt may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company (&#147;DTC&#148;) or another depositary named by
Calyxt and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will
be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the
limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized
denomination and of like tenor and aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to
global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly
executed if so required by Calyxt or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by Calyxt for this purpose. Unless otherwise provided in the debt securities that the holder
presents for transfer or exchange, Calyxt will impose no service charge for any registration of transfer or exchange, but Calyxt may require payment of any taxes or other governmental charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will name the security registrar, and any transfer agent in addition to the security registrar, that
Calyxt initially designates for any debt securities. Calyxt may, at any time, designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that
Calyxt will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Calyxt elects to
redeem the debt securities of any series, Calyxt will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part,
except the unredeemed portion of any debt securities Calyxt is redeeming in part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a trustee to be named in the indenture. The trustee, other than during the
occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same
degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of
debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and
Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, Calyxt will make payment of the interest on any debt
securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by it, except that unless otherwise indicated in the applicable prospectus supplement, Calyxt will make interest payments by check that it will mail to the holder or by wire transfer to certain holders. Unless otherwise indicated in the
applicable prospectus supplement, Calyxt will designate the corporate trust office of the trustee as its sole paying agent for payments with respect to debt securities of each series. The applicable prospectus supplement will name any other paying
agents that Calyxt initially designates for the debt securities of a particular series. Calyxt will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money Calyxt pays to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities
that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to Calyxt, and the holder of the debt security thereafter may look only to Calyxt for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities, and any claim, controversy or dispute arising under or related to the indenture or the debt securities, will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture
Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt may sell its securities in any one or more of the following ways from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in &#147;at the market offerings&#148; within the meaning of Rule&nbsp;415(a)(4) under the Securities Act, to or
through market maker or into an existing trading market, on an exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers, including through a specific bidding, auction or other process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt may issue the securities as a dividend or distribution or in a subscription rights offering to
Calyxt&#146;s existing security holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will contain the terms of the
transaction, including the method of distribution of the securities offered, the proceeds Calyxt will receive from the sale, the name or names of any underwriters, dealers, agents and the respective amounts of securities underwritten or purchased by
them, the initial public offering price of the securities, and the applicable agent&#146;s commission, dealer&#146;s purchase price or underwriter&#146;s discount. Any dealers and agents participating in the distribution of the securities may be
deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
initial offering price, dealer purchase price, discount or commission may be changed from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be distributed
from time to time in one or more transactions, at negotiated prices, at a fixed price or fixed prices (that may be subject to change), at market prices prevailing at the time of sale, or at various prices determined at the time of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by Calyxt or by agents designated by Calyxt from time to time. Unless otherwise
indicated in the prospectus supplement, any such agent will use its commercially reasonable efforts to solicit purchases for the period of its appointment or to sell securities on a continuing basis. Agents may receive compensation in the form of
commissions, discounts or concessions from Calyxt. Agents may also receive compensation from the purchasers of the securities to whom they sell as principals. Each particular agent will receive compensation in amounts negotiated in connection with
the sale, which might be in excess of customary commissions. Any such agent may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities so offered and sold. Accordingly, any commission, discount or concession
received by them and any profit on the resale of the securities purchased by them may be deemed to be underwriting discounts or commissions under the Securities Act. Calyxt has not entered into any agreements, understandings or arrangements with any
underwriters or broker-dealers regarding the sale of their securities. As of the date of this prospectus, there are no special selling arrangements between any broker-dealer or other person and Calyxt. No period of time has been fixed within which
the securities will be offered and sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are utilized in the sale of any securities in respect of which this prospectus
is being delivered, such securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at fixed public offering prices or at varying prices
determined by the underwriters at the time of sale. Securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by one or more underwriters. If any underwriter or underwriters are
utilized in the sale of securities, unless otherwise indicated in the applicable prospectus supplement, the obligations of the underwriters are subject to certain conditions precedent, and the underwriters will be obligated to purchase all such
securities if they purchase any of them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which this prospectus is
delivered, Calyxt will sell such securities to the dealer as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. Transactions through brokers or dealers may
include block trades in which brokers or dealers will attempt to sell shares as agent but may position and resell as principal to facilitate the transaction or in cross trades, in which the same broker or dealer acts as agent on both sides of the
trade. Any such dealer may be deemed to be an underwriter, as such term is defined in the Securities Act, of the securities so offered and sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by Calyxt, and the sale thereof may be made by Calyxt, directly to institutional
investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters and dealers may be entitled under relevant agreements with us to indemnification by us against certain liabilities,
including liabilities under the Securities Act, or to contribution with respect to payments which such agents, underwriters and dealers may be required to make in respect thereof. The terms and conditions of any indemnification or contribution will
be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents may receive compensation in the form of
commissions, discounts or concessions from Calyxt. Underwriters, broker-dealers or agents may also receive compensation from the purchasers of shares for whom they act as agents or to whom they sell as principals, or both. Compensation as to a
particular underwriter, broker-dealer or agent will be in amounts to be negotiated in connection with transactions involving shares and might be in excess of customary commissions. In effecting sales, broker-dealers engaged by Calyxt may arrange for
other broker-dealers to participate in the resales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any securities offered other than common stock and preferred stock will be a new
issue and, other than the common stock, which is listed on the Nasdaq Global Market, will have no established trading market. Calyxt may elect to list any series of securities on an exchange, and in the case of the common stock, on any additional
exchange, but, unless otherwise specified in the applicable prospectus supplement and/or other offering material, Calyxt shall not be obligated to do so. It is possible that one or more underwriters may make a market in a class or series of
securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. No assurance can be given as to the liquidity of, or the trading market for, any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters and dealers may engage in transactions with, or perform services for, Calyxt or its subsidiaries in the ordinary course
of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in
accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids
do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession
from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the
underwriters may discontinue any of the activities at any time. An underwriter may carry out these transactions on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise.
The underwriters or agents, as the case may be, are not required to engage in these activities and, if they engage in any of these activities, may end any of these activities at any time without notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The place and time of delivery for securities will be set forth in the accompanying prospectus supplement. To comply with applicable state
securities laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions only through registered or licensed brokers or dealers. In addition, securities may not be sold in some states absent registration or
pursuant to an exemption from applicable state securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus will be passed
upon by Jones Day, New York, New York. Additional legal matters may be passed upon for any underwriters, dealers or agents by counsel that will be named in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Calyxt, Inc. appearing in Calyxt&#146;s Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the
year ended December&nbsp;31, 2021 have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements
are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst&nbsp;&amp; Young LLP pertaining to such financial statements to the extent covered by consents
filed with the SEC given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_14"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows Calyxt to incorporate by reference much of the information the Company files with them. This allows Calyxt to disclose
important information to you by referring those publicly filed documents. The information that Calyxt incorporates by reference in this prospectus is considered to be part of this prospectus. Because Calyxt is incorporating by reference future
filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that Calyxt
incorporates by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38161)</FONT> and any future filings the Company makes with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not
deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000095017022002808/clxt-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December 31, 2021 (including the information in Part III incorporated therein by reference from Calyxt&#146;s <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312522109435/d549519ddef14a.htm">Definitive
 Proxy Statement</A> on Schedule 14A); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522142416/d327324d10q.htm">March&nbsp;31,
 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522212583/d368508d10q.htm">June&nbsp;30, 2022</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather than
filed) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522046086/d197864d8k.htm">February&nbsp;
18, 2022</A> (solely with respect to Item 8.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522049605/d297063d8k.htm">February&nbsp;
23, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522086783/d340165d8k.htm">March&nbsp;
28, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522156143/d320217d8k.htm">May&nbsp;
20, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312522166294/d337451d8k.htm">June&nbsp;2, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of Calyxt&#146;s common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312517231512/d433769d8a12b.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A> filed on July&nbsp;20, 2017, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt also incorporates by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, until Calyxt files a
post-effective amendment that indicates the termination of the offering of the shares of Calyxt&#146;s common stock made by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC.
Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document Calyxt previously
filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc385878_15"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, is required to file
periodic reports, proxy statements and other information with the SEC. You can read Calyxt&#146;s SEC filings, including the registration statement, over the internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt makes available free of charge, on or through the investor relations section of Calyxt&#146;s website, Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after the Company electronically files such material with, or furnishes it to, the SEC. Calyxt will provide without charge to each person, including any beneficial
owner, to whom this prospectus is delivered, upon his or her written or oral request, a copy of any or all of the information that has been incorporated by reference into this prospectus but not delivered with this prospectus, excluding exhibits to
those documents unless they are specifically incorporated by reference into those documents. You may obtain copies of this prospectus and the documents incorporated by reference without charge by writing to Calyxt&#146;s investor relations team at
2800 Mount Ridge Road, Roseville, Minnesota 55113, by telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(651)-683-2807</FONT></FONT> or on Calyxt&#146;s website at www.calyxt.com. Information contained on our website is
not incorporated into this prospectus and you should not consider information contained on our website to be part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g385878g59u88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 15,661,000 Shares of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:75pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies </B></P> <P STYLE="font-size:75pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;3, 2022 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>d385878dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that
offering is $2,662,370. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g385878g00m03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g385878g00m03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/2^8X@X0DE-! 0      #<< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  ;4F%Y;6]N9"!!8FEY82!%9'=I;B!#:&%R;&5S #A"24T$)0      $$+S
MPEQB3GNSF.)2?=#RU:$X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8@
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              :P
M 6L          0                         !              %K
M:P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M:P    !29VAT;&]N9P   6L    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   &L     4F=H=&QO;F<
M  %K     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M2?KJ_,Z8QOI?6+I;2*;W-]-N1L.W(QGM=[_2KO\ T?Z3WT6?K>/^B]6M:_\
MB[^LE_5^G68.<YSNH=.(9:ZSZ;ZS+:K+/SO6K=79CY'\NOU/\*FRCI8%=PNB
M;KQ>N0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,SE"0U)X@K71X?_$ !L!  (" P$                %! 8! P<"_\0 0Q$
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M?FA;\K0JCL# ))$$ B8G27>+T4;=Z2?[UH'P>.228,P9 /V!^(*FMA#0_C7
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MC)7#E7>T5I&0ZZ"L<BC3TY]P=NRC7#9!=JD2..1J=(BZ!/-23(/A_2N^4_\
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M'T#D!]^!'DG=Q[#QUR&D PJ(T2&98\$XP>HG/F>CYUT]F"JKJ9! /Z R1UW
M@GJ,_&?GX[I37)6Y?NNHXLQX+EU5X6VUK3ECI8J9E6+!G&R23G(MS,7D1]*6
M?&UR[@Z?>88NMQIE%2(@@<W6=D-'8_3K7CD5:K&30_)!G #_ -9( DX3L P#
MKFFY;A2W/>&VZW)9F/$U.(*+*D$E0WN 8QELJS $>+SU=T[8JJVGR'TV)5B.
MD</Q.-F>*3U.30*M'R%,:PA:^HPDB>XJB[8%.9XX$WF'6.HN)R*#YI>:W%U4
MKWOXL-]+^L:J47WJ9/(*I)$ ' G$$R)QJ_T[:FMN:##G*A>94+]N1CY.3$$Q
MDG)U09SQI?U#;+NX56L@83^(R-/A)Y[;L0SSA=P#3(.+)-5%C:\8VM0B:Q3N
MXIJZD*E/@N4ZI%$XRV1R7K%8XA.H6US3]2[&U)J:4J])FIEN0JLQIJA5@L*5
M&<2Q)R1+#% W6LGI[<:52H[_ $"JL'XA .1=62)/1 !. 3*D!23J5>]+N.V'
M7O!XJP'IWBK.UPVK%5J\Y&9JQ\BE,6S)THFB\A:"LU2;@=ZVH#HZK54S,[IM
M+7%P46@%"&CG2^GTULB;:ES?WH7BG*DA(ZY04(.0"P0^">A((.O.Y>J+;<7I
M6UF6JEQR@$ 3QF#))8*7'@##1R4\38(V4-L]CH)TVI2MX8MCZB\R(QU@RR^%
M))16NM&R2X5O'+%R558!9UEL\.K**I&!.3GW3UP'FM6\><M+]1[Q4O[EJ*.3
M10D( Q(F .0QQB![<8!/NDF+CLNWI;T4K-3XU743*@,.SGR"29(.) CH'2C=
M_P VT=-N)L:!J<P[1IQEG++NH91WD">5MEGF&<@C9J_=;#-';5]](N(>,*O+
ML&*A CV3?R02$I! %3!U8/1FYUGOGH.04-,X)."!"B3,1\'O[>4GJ:E0LK:G
M= 95XCKER(F2)R8B#T1GN-9;..S-HJU7:-6&5M26,;)/Y+=Y)O\ !KR##(=Z
MK+<86(>LB1:!HJ$G&#$%4/.< 9?R?-4 Q2J&,!"\>O4V^WUEN=2C:UBM+Z5)
MBH9OS-S#'#0)@>.Y^-&PV%GNED+BHD-]5T&$,JH4B93LSGQ F,G5J+39I@PW
MI(Q56\+8'JB%,Q[50D#QL41=U(O%GLO(.I26DY28D5W,I+24B_=K+N'LBZ<K
M 7RVZ1DVR22)*'=75U>56J5ZQ8$'VD'!F<-RF)S'4Q\9N%O:T+50E) #!]V,
MQ Z ^(C.!(Z.) \&_P#-^_'_ ._OU' (\G_)\=P/$?X:DZYZSHTC_-&=MG6N
MZ[$J!F*FXE/K<5R%BQB2>FL%S<I<CWB58UA7&;Q/(05%RP%TR8NZZ,9*!,E2
MC$$F[4ZZ8ME2=/K6WW1MOK5J*U#:(K?481Q6 9!Q(QCYDD@]$)*U>SJ7J4VX
M?65E'4$', DY)GN/ $X.DK>)]J<O/ZE=+#HJ2OPP<,7!FQ*8W+;XJ2ZI.WWD
M%^HKIH.(L7)R#]%6XCPF!.+;_P!')#6]RWYCS!)!.)!@23,_) [,"/%:]7U6
MI7UNBD*Q0P#F5)@S@P#(6,GO C+*]R_/4WIOVIM,F5\;X_IF0J^Q0P+ /82V
MIS 0#.$F<>NX]A))%KLG&N06++MXY!'M< @F+E8JB9CG*(*O3U%;C>Z].H0*
MBI4?W3+,'$KF#CD3$@0 9( !/4>W+O'IVU^HYHDM2;C.9"1!'Y3@$Y^(&I7;
M(.HVOZE]"M=R(E7JI4K<G?\ (,#?*O4?B(1$-,Q=B<A!BD67?R<D7XC21J\D
M=5TZ$'+ERJLF7\THG5>J*%5=SJ?5+!.%, ,<!5'Q]R9!SY\#3GTI1IVVU4;:
MBO)T9@2(Y$DAC/B5)@Q Q) :1IP+DY#(E.0Y2%*8HBH8O<!0$?8/?V$1-P//
M/UX_7JN@K37,!1C/0,X/P?T_;K5F97F%;@X,3B8\K/B0?\G2^]>.J70WIL@<
M>O=:DS6&D5<)>7CZ"VG:1,79RYDXM@W5GW#*,AH:7=L4VD>^9(.9!1!)(%'3
M=F"A7!R@#/::-[>U"NWAG8 SQ\&#]B)&20>LDYQI1NR[>B*=RH)7$PH=5<RQ
M$F23 /M$R)@?;42M=V3<!9-V5]1&1\+>A'"5OP78EZ"=*MR%9:+.'UJ)#0Z[
M:!EF48^CTW5N*B=F"[) SH5$7C?N171'IEM*W9]54K:I38UU)YH",$4WF0(]
MH )(\0))S,*^6B^QS;D,I9>(7N!50D#N"8&9'1@0<+7\*FDNCA'64_>")8 V
M0\=H-S' ?3^M0I]C7EP 0#@3#'NXDZQ2B(@8X ?W4 .G?K=U.XV*T&#5%158
M"91Q4!63 !GD&Q.<:T>GE%5;Y%'-5I(& (.66H&4@P)7(&!@#H :7#X;T#/-
MT:_/(TX&BPPIEY43I>Z96;FZ4T61@[?E /E;%(/T 1#MXY#EKZN<#9+5B.3\
MJ"$3UR26G]U S@F9GO2G88?<&6F85.0<Y@<6<()'R28,8_8G4U_$!ZM;/IZU
MB4^N(X1QSD6,L&$ZY/0DS<EK<D_.H2R6R/E8UG\$L$6P519.6[!14AVQG!3/
MA$%2^:'.CT=;BZV^M3I9KAC[/XCEB#W!@P(SW]]1?5FQT]TOJ?U:Q10GM(&!
M $SD= ,9Z[R)!U;%T^6:JVS".(K%2C,_PM8<9TF<K9&)RG:IPDG78QY'MVYB
MC\R;5FNW1 PB8 $!+\IP,'7-[H?0KFG7;@X8I#9,C!F) EI F('ZG5^V^FJV
M%%:<$)313 B.*@"9@F1V?TGQK=)S-P'\TQ2B4I0$3#[% >>T3&XX+R8H\"(@
M F+[>_MU',9SQ)_3K_&,?.IP&.I Q]L1(S/6)&8\Z].Z?Q#8Q1,NU35\X"<F
M,1,2B<H)F$QN!#GRP   P=HB!!'@  P9-*L5+*781+=D<<23D]1@'$_?4<UZ
M".%)56)XC $DF,&/D?O^^J3F\[K+D\ [CECH%KP;C*WT\('$<RA<[4O<0EUJ
MG+PK(TT9!O&V%A$K(Q<HTL39,GI5"@JF7SA$Z?R]2]-T&'I\UZ&26?E&&E'8
M$$X[&9C (SKFF_[,C;VUY5K&&" 4P"5@HJ+,S!9L8[. !G5URLOX&3B(A_7S
M,G$2^BV#R*<L3HG:KQ3M$BT<X;&1_+.V<-A3.@HF(I*I@ IF,!0 .85D57AW
M'/Q\D^<F>L_KKIEO5^H@:FOL@$\< 2) /4X[Q'\M=@443 IA-V@4!-W";V#C
MD.1$1#CM]QYY]@#W$0 !ZU."5,B/[\'S_?\ RUN43^43G[]Q]_,#]_UU3'W_
M '6C 8&U<5"D0.)L89+FTL*,)ZUN[@O:0D8M5Y8;&6#B@)7)Z)(5 [!J1^0'
M+<SA%-V13DR"I._J?I2W<[9<$$G^KJJJYR.($QU[6#*3F"? F.8>I["E>7](
MJY5Z=6BT !H4,Q8F>(@JZ\>B8C4_=US/*V(MJ#3MEQ+'U1M9II; B9:A/JSA
M(%@-CH+AP)FBL7*LI'_=Q2*(L2J.3)'2,!EP.8YNDOIZW9M[KTAW3:KD_'(S
MY\3Y( Z,Y.F>_P!F*^R6M(.26%/\H!.$$?F@"8$_\/VUOO8'S0YS_HCE+XXH
MU6Q]Y>:+[ G@*F>85BO]WL:XL+WNG).5>>J<^L_/*#KR2BF4$B%*''4/UC2C
M<E5F]P17,>,F/W/<R>X\:G^D+;\)8-34DI]0@DB)(B>L0I! Z!@'O4/?$(2$
MWII#$VJ&JX7QUD6#MLJYQMD:4M);.WDH.=9-"RE#>IJ5R?AD'3:8:H3<8LJ]
M*+EFYB89)!<4'*B167H^LMS5JV%6H"OT_:A),S(8 ?91!S$GK,Z5^J]D6O<T
M+\,:380E>QP/(2<_FY1\0"3F-2BK^[-7EMG%UKW70B4[Q%49S2W%-,\>JM0S
MJG.GQZPKA52N1E#-7LT9M8CK%>'D K3PLB9P4#)JE6U=B>GOXL53VO5%0#L&
MD#R+'L1)(\1'D" \3<0FSLQ<%EHM1)$J>;"% P#(7/G/9Z&H9[ LU8-4]FRW
MJ:M6%,94*$QD\0I%'L58/;'LK/WBS,%I"YJ=]BL$JV0:0->-"QRKENW3?/7-
MD, JE,E*$7:>KW2TJ6^W4W 1J?)E4G'Y3+#(S@K\P9 U6/2?IY;6O=;L:C5Z
MI=LN((+<CWW.2",Y8$3 U:I.1,A2 <P  < '(?\ >/\ * !]>1,(]H 'N//
M<B( //O:"%+9,  ]_MW$]1\=SKI@F!"SB<1@8_3YU7IW^=8^#M.>%Z%3IZEU
M?*F;KC/IRV,:G.NW;=G6H>&=-DK;<II2(7:RB,0M'NS031LF[;EEIAPU43%1
MI"RZK2\^BK"ZK[A4XUC3H+1!=22.1]ZK@0))(((,@+D &=4OU=1L]VLUVMU7
MZQ;ZH<"6II*X!\@FGQ ,"6/$EL:KR[?VZ)B&*U:8C'43I]Q-2\>NK$@P&]UY
MS;15H-AD6X(U6V2+*PSLDP=P#:0%F60/Y"9XYJJ2:07\N*.12X[S970VJZHV
MU7ZZBM39OIDP.'*<L<F"1.8F<P1JF['L5GMNX4JH8/3IHZ%F$KR. " !^4B0
M)$C R1KZ$T<NV7;$7:*)N&ZB::J"B(E.BJDHF0Z:J2I.2*IG3,4P&()BB(F[
M/E ..+D,*]16PTYY2,XQYZ$ _>9@1'8T=#20IE0H@@]S&<8_4YGS\:1'X@;-
M2FGS2-0+RC1*GD)5SG*OU\D)<CS9(Q$CRH71T=^E\ DHMX+E,C4Z) .Z @I+
M+=R9OE$MN]%4P=T<!C^0D? @,2,"9DS$^3X@:JOJ^S6[V^G3+<?ZQ>NP9@ 8
MS,D_,QXG6S]AO+RN<=!4+D!:EUB@JO<HY*CSUVHGEE(5$T5)M&1G:1YJ0DGY
MEGIDQ<+B=R)1.?N @&$YC>/5R<-V<$G-&D1/Q[QC]_\ 01K;Z3MQ:[=]$,6"
MUJA!;O*H<QC GY_4Z=%U5M6CR/T/_+_WT=&LZ.C1J@_XD7&MJP7N%X@U1U5)
M9HID2FU"SP,P"8E;%R-@::CVADU5 *1+ST(U[3G)2F6Y70,8 *)4#"'2_1_^
MV[1>6?ER97P?S#_%AT8QU@Q0=^I5J=XM2@>+?5IN6DAN"B&P#+24!) Q/>2-
M.YW+L>US7]HKTSZP<:-22B5<8,[TD5MVN'K6DY/BX=E9&(F2 QO/K<U'0J<N
MEV&\E1B^(8J7:L8B?T_=-LF]U]J)X_4J$!08!XS!@P?RP>A$#YUI]74:FY[%
M2W.U ^O16&_M@RO(2)@!PP,29..M=^TZ8]IVN+;INFAC+R@M%$Z<I4V$J)07
M<Q[!G*DG\=6V+3 S<ZCVCRS:(6(@DJV!P:*: HJ#&25 AZA^IM&YTMYM)6WJ
M.>17V$$J P.# *GK()R2#G6CT1NE/?-KJ;5<F;J@"5#02022AB26*L1. >+#
M!!;567"^>M;6P'J=N6.[[25)NF65Z@-JI$D>0:8_RQ&1?J&<1D;&5P39NT8^
M50;ONY5RBR=JMR.%JY98?SFS))E9Z]KMOJ:PIU_K+3NG3AQP6!6)D"#TP/R
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MC3K3LE9DR"Y:G3@V-AK;S'50CGITE.QQ/RTT89Q1-(QN\6E?A':SP42-PE&
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M$Y4'_P!1^F=25\,+_P!G'-_^HS)W_P 53N?]>?[NH7K3_O@_^"G^)U-]._\
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M[LV!"%;%47386ULR1,D^_$"JC)%-Q?>D4O%_$[542W8<2M- 2LQV& 4J3 $
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M,TK956FIF&;C,D@$@Y,3VR@3)DF7M/I7;["O^.1%%S4]S>Q0 2<E"(X@J8
M*J9X!1 #<BD H@/W#GWX !$1X^H_L'L']1ZK8$?<_/G5N\S_ )S_ *:SZSHT
M" #]0 ?Z]>0N,Y_71K$ $/O[?IP ?X=9@#H ?MKR W]J?V&LNLZ]:.C1K@0
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C&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g385878g14w41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g385878g14w41.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1F*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &6Z^91 X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "%)2,3$W
M-3<R' (% $!-:6-R;W-O9G0@5V]R9" M($-,6%0@+2!0<F]S<&5C='5S(%-U
M<'!L96UE;G0@,C R,B!!5$T@4F4M06-T:79A #A"24T$)0      $%B4Y;3>
MU-(6WJLG0NL]BH8X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8V            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$1       $     (   )    "0
M   X0DE-!!X       0     .$))300:      ,[    !@
M:0   6<    # #  ,  Q     0                         !
M      %G    :0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    :0    !29VAT;&]N9P   6<    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &D
M4F=H=&QO;F<   %G     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,      [*     0   *     O   !X   6"
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M5[W?2>QPG'O?_P (]K7U6_\ #4T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MXQJ4'8M=1IE&>I?MGC>7=UU6P/$GP6%!O>H9>'72="=%+QM5)1T#0P!X&Q0
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MQBI(I)F4./@*(]<V0A3JT-MI)<<(2D 29/ Q_23S%.KCB&FU.+("$ J420!
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MB!(6&R2AN7<U89=8OS$E*/#J.'"P^$IB-TT4$>8WU]<W]R]=73I4IU2B!N)
M!)C:#QCL!V'<5U>SM&[-AJW;2/8!N44@DXR5*[DG@_;CG2>_&AV%]\<$6K%N
M3ZS$KSGT]X[QY?RH 2RX_MR+=?Z1,P\D0OS1&9')B)R\68RD?+L#*-GC1;^&
M*<C1M4NM+NVG+9Q9;*OVS:EJ4E2<8*28)YCP1/:HVK:>Q>VKH4V@/)0?3<(
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M.1%%,AE%CD3 QRK2$*=*4-IW%9@) &2?@9)Q  [_ &J\<<2TA3CA"4I$J)P
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M[0_</4.?0>0^W7*U'VDJ$[!(CDA(D3Y)X./]UT)([\%1SG /!\P*3O\ B/\
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M5$!$4Q7DJVBX,0$W;\4R%#H<ZET#2D+.EVZ775@[0VWL ,&-RR)(!V@@ &(
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MYT6;4I648P)\FHGZ_P!0O:NX&V@6K%/#4[B3&"3B1C F.^2 0P:-HC6G NN
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CHZ**.BBCHHHZ**.BBCHHHZ**.BBCHHHZ**.BBCHHHZ**_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g385878g59u88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g385878g59u88.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1C\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &."^8V@X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "%)2,3$W
M-3<R' (% $!-:6-R;W-O9G0@5V]R9" M($-,6%0@+2!0<F]S<&5C='5S(%-U
M<'!L96UE;G0@,C R,B!!5$T@4F4M06-T:79A #A"24T$)0      $%B4Y;3>
MU-(6WJLG0NL]BH8X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8@            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$1       $     (   )    "0
M   X0DE-!!X       0     .$))300:      ,[    !@
M:0   6H    # #  ,  R     0                         !
M      %J    :0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    :0    !29VAT;&]N9P   6H    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &D
M4F=H=&QO;F<   %J     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,      X\     0   )\    N   !X   5D
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MAF_-_9'UCQ_V;U$$,:\@LK<\_0KLKM]^+98T_H??9CW_ .#N_FZU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     /_A06-H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#<N,BUC
M,# P(#<Y+C%B-C5A-SDL(#(P,C(O,#8O,3,M,3<Z-#8Z,30@(" @(" @("(^
M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z<&1F
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z=&EF
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(@H@
M(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3$P+3 Q5# Y.C R.C0P
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C(M,3 M,#%4,#@Z-#(Z,S$K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3$P+3 Q5# Y.C R
M.C0P*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P
M9&8Z4')O9'5C97(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @
M/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!#3%A4("T@4')O<W!E8W1U<R!3
M=7!P;&5M96YT(#(P,C(@051-(%)E+4%C=&EV871I;VX@,34S,S0V.#0W,RXU
M+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^4E(Q,3<U-S(\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C
M.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z
M9F]R;6%T/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.CDP
M,S1A8SDQ+3)B86$M8F4T,BUA930Q+6$W93@T8V$S93-D-SPO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C
M:60Z<&AO=&]S:&]P.F1A,C,X8C@Q+3@W.3$M,V8T92TX8C4Y+3@R-C8P968S
M8SAB-3PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C@Y8V)F9&,W+3$Y.#@M,F0T-"TY9C,V
M+3%A,V1C-F4V9C0W-SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z.#EC8F9D8S<M,3DX."TR9#0T+3EF,S8M,6$S9&,V939F-#<W
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(R+3$P+3 Q5# Y.C Q.C4W*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F-A
M9#0U,F9C+65E83<M,3@T.2UA9C$P+3$V-C8U9&9A8S9C,SPO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ
M,"TP,50P.3HP,CHT,"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S
M+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.CDP,S1A8SDQ+3)B86$M8F4T,BUA930Q+6$W
M93@T8V$S93-D-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,BTQ,"TP,50P.3HP,CHT,"LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI
M:60Z8V%D-#4R9F,M965A-RTQ.#0Y+6%F,3 M,38V-C5D9F%C-F,S/"]S=%)E
M9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX
M;7 N9&ED.C@Y8V)F9&,W+3$Y.#@M,F0T-"TY9C,V+3%A,V1C-F4V9C0W-SPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.C@Y8V)F9&,W+3$Y.#@M,F0T-"TY9C,V+3%A
M,V1C-F4V9C0W-SPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \=&EF9CI/<FEE;G1A
M=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@(" @(" @(" \=&EF9CI84F5S
M;VQU=&EO;CXQ-#0P,# P+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@(" @
M(" @(" \=&EF9CI94F5S;VQU=&EO;CXQ-#0P,# P+S$P,# P/"]T:69F.EE2
M97-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI297-O;'5T:6]N56YI=#XR/"]T
M:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @(" \97AI9CI#;VQO<E-P86-E
M/C8U-3,U/"]E>&EF.D-O;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.E!I>&5L
M6$1I;65N<VEO;CXS-C(\+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(" @(" @
M(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^,3 U/"]E>&EF.E!I>&5L641I;65N
M<VEO;CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S
M:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
M<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !& /$# 1$
M A$! Q$!_\0 'P   @(" @,!              D("@8' 0L"! 4#_\0 0A
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MF(TWL$;7=GJ\YMK4YRD+7]B\,+8YG)%)!0AG01=FKL/27#EP)%2%,Y7;3*2
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MJX>/GCM9-NV:LVJ1EG+IPNL<B:#=NB4RBZYS%213 553D3(8P)54LP1!+L<
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M:R94;SD*TY,BYV:8UR@JP!7T- PCIHR^\S(3LG&II,Y.0=&8QPI"JHLJQ?\
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M4]2XM),*B]SD8':>U1Q!Y$P2, D%D//[A"H[=<=6)M_:S7$8>_XH0J4K,'*
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MU&J,U-"5H(3[521[H'R!/F/DY.NC[/8K:VB]R#UJB+ZKD2S,!G)S ).(CB
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M4BDQ5BHR"98@-,]J@^V(!C$@;SL?+O%MN$AAND@I ES!.U5OA5&N*%=*Q/\
ME!JF6JLJT*S1=D?_ &I C20O*;47Y7:< "132)W _4*+$V CJ9[$"*:515+
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M*ZFQZ&N_5IF]=:=,0> _<(R)#CM,P#\3SY#6]ZD5J)2VIU.ZHHAF1E[9Y'N
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M2C,-@^IRYAVO \Q1,2+D#+WG#T4C'L6T*994A3.K!CX%$(\_NK.'C^KFCW0
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MYZV3"YY&Q32WY./U4BNJFT(<YOI8U!BR(!4VR90H^Z7S[C?5[A_WF]HR %R
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M\#[<R?IK=VP&KV!=I*Q#4W8+%-3RS6*].$LT+!VZ/^XL(Z>282$4G*-DO=3
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M$\C64PUL].YQ1)DN%#D:'F/-$* N(B0A):0V.RHYE6IO(AXR1!>0Q_C]RF<
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D-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
